A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright Ó2003 by ICON Group International, Inc. Copyright Ó2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Leukemia: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83711-2 1. Leukemia-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on leukemia. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications.
Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON LEUKEMIA ................................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Leukemia ....................................................................................... 5 E-Journals: PubMed Central ....................................................................................................... 63 The National Library of Medicine: PubMed ................................................................................ 97 CHAPTER 2. NUTRITION AND LEUKEMIA ..................................................................................... 187 Overview.................................................................................................................................... 187 Finding Nutrition Studies on Leukemia .................................................................................... 187 Federal Resources on Nutrition ................................................................................................. 202 Additional Web Resources ......................................................................................................... 202 CHAPTER 3. ALTERNATIVE MEDICINE AND LEUKEMIA ............................................................... 205 Overview.................................................................................................................................... 205 National Center for Complementary and Alternative Medicine................................................ 205 Additional Web Resources ......................................................................................................... 235 General References ..................................................................................................................... 240 CHAPTER 4. DISSERTATIONS ON LEUKEMIA ................................................................................. 241 Overview.................................................................................................................................... 241 Dissertations on Leukemia ......................................................................................................... 241 Keeping Current ........................................................................................................................ 248 CHAPTER 5. CLINICAL TRIALS AND LEUKEMIA ........................................................................... 249 Overview.................................................................................................................................... 249 Recent Trials on Leukemia ......................................................................................................... 249 Keeping Current on Clinical Trials ........................................................................................... 271 CHAPTER 6. PATENTS ON LEUKEMIA............................................................................................ 273 Overview.................................................................................................................................... 273 Patents on Leukemia .................................................................................................................. 273 Patent Applications on Leukemia .............................................................................................. 303 Keeping Current ........................................................................................................................ 340 CHAPTER 7. BOOKS ON LEUKEMIA ............................................................................................... 343 Overview.................................................................................................................................... 343 Book Summaries: Federal Agencies............................................................................................ 343 Book Summaries: Online Booksellers......................................................................................... 345 The National Library of Medicine Book Index ........................................................................... 360 Chapters on Leukemia ................................................................................................................ 361 CHAPTER 8. MULTIMEDIA ON LEUKEMIA .................................................................................... 363 Overview.................................................................................................................................... 363 Video Recordings ....................................................................................................................... 363 Audio Recordings....................................................................................................................... 364 Bibliography: Multimedia on Leukemia..................................................................................... 364 CHAPTER 9. PERIODICALS AND NEWS ON LEUKEMIA ................................................................. 367 Overview.................................................................................................................................... 367 News Services and Press Releases.............................................................................................. 367 Newsletter Articles .................................................................................................................... 371 Academic Periodicals covering Leukemia .................................................................................. 372 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 373 Overview.................................................................................................................................... 373 U.S. Pharmacopeia..................................................................................................................... 373 Commercial Databases ............................................................................................................... 376 Researching Orphan Drugs ....................................................................................................... 377
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 385 Overview.................................................................................................................................... 385 NIH Guidelines.......................................................................................................................... 385 NIH Databases........................................................................................................................... 387 Other Commercial Databases..................................................................................................... 390 The Genome Project and Leukemia ............................................................................................ 390 APPENDIX B. PATIENT RESOURCES ............................................................................................... 397 Overview.................................................................................................................................... 397 Patient Guideline Sources.......................................................................................................... 397 Associations and Leukemia ........................................................................................................ 406 Finding Associations.................................................................................................................. 407 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 409 Overview.................................................................................................................................... 409 Preparation................................................................................................................................. 409 Finding a Local Medical Library................................................................................................ 409 Medical Libraries in the U.S. and Canada ................................................................................. 409 ONLINE GLOSSARIES ................................................................................................................ 415 Online Dictionary Directories ................................................................................................... 417 LEUKEMIA DICTIONARY ......................................................................................................... 419 INDEX .............................................................................................................................................. 515
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with leukemia is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about leukemia, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to leukemia, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on leukemia. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to leukemia, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on leukemia. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON LEUKEMIA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on leukemia.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and leukemia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “leukemia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: ·
Chronic Lymphocytic Leukemia of B-Cell Origin: Oral Manifestations and Dental Treatment Planning Source: JADA. Journal of American Dental Association. 128(2): 206-210. February 1997. Summary: Chronic lympocytic leukemia, or CLL, is the most common form of leukemia in the Western Hemisphere, accounting for approximately 30 percent of all cases. With patients having an expected life span of more than seven years, CLL is a relatively indolent hematologic malignant disease that, while incurable, often has a prognosis compatible with relatively normal dental treatment planning. In this article, the authors present four case reports of CLL in a dental setting. The authors provide an update on the diagnosis, prognosis, and dental treatment of patients with CLL of B-lymphocyte origin. Surgical considerations for procedures such as tooth extraction, periodontal surgery, apical surgery, and implant surgery in patients in beginning or intermediate
4
Leukemia
stages of CLL usually are dictated by the patient's desires, masticatory needs, and expected life span, rather than by inherent characteristics of the hematologic malignancy. 1 table. 15 references. (AA-M). ·
Gingival Hyperplasia Complicating Acute Myelomonocytic Leukemia Source: Journal of the Canadian Dental Association. 66(2): 78-79. February 2000. Contact: Canadian Dental Association. 1815 Alta Vista Drive, Ottowa, ON K1G 3Y6. (613) 523-1770. E-mail:
[email protected]. Website: www.cda-adc.ca. Summary: Many systemic illnesses show clinical signs in the oral cavity. This article presents a case report of gingival hyperplasia (overgrowth) that was the first symptom of the presence of acute myelomonocytic leukemia (AML FAB M4). The authors review the oral manifestations of acute leukemia. The authors note that gingival hyperplasia is secondary to infiltration of the gingival tissue with leukemia cells and is well described in the literature. Generally, gingival hyperplasia resolves completely or at least partly with effective leukemia chemotherapy. This case reminds dentists and physicians of the importance of recognizing mucocutaneous manifestations of systemic diseases. 2 figures. 10 references.
·
Risky Decision Making and Allocation of Resources for Leukemia and AIDS Programs Source: Health Psychology; Vol. 12, No. 2. Contact: University of Iowa, Department of Psychology, Iowa City, IA, 52242. Summary: The goal of this study was to apply established judgement and decisionmaking paradigms to identify and understand underlying reactions to persons with AIDS compared with persons with another, less responsibility-laden, blood disease, leukemia. In the first experiment, each subject responded to treatment options for either leukemia or AIDS but did not compare the two. In the second experiment, the subjects were asked to consider treatment programs that would affect both AIDS patients and leukemia patients. In the third part of the study, subjects evaluated treatment programs described by both the number of leukemia patients saved and by the number of AIDS patients saved. In all three cases the subjects were psychology students. The results indicate a preference for less risky treatment options with positively framed information and a preference for saving the lives of leukemia patients over AIDS patients.
·
Acute Promyelocytic Leukemia in Crohn's Disease Source: Journal of Clinical Gastroenterology. 13(3): 325-327. June 1991. Summary: This article presents a case study of a 19-year-old man with a documented 2year history of Crohn's disease who abruptly developed leukopenia and thrombocytopenia. A diagnosis of acute promyelocytic leukemia was established by bone marrow cytology. Chromosomal analysis of bone marrow aspirate was performed. The authors note that nine cases of Crohn's disease complicated by leukemia have been reported, including the present one; once again, a relationship between Crohn's disease and leukemia is suggested. 1 figure. 10 references. (AA).
·
Incidence of Oral Complications and Application of a Preventive Protocol in Children with Acute Leukemia Source: SCD. Special Care in Dentistry. 18(5): 189-193. September- October 1998.
Studies
5
Contact: Available from Special Care Dentistry. 211 East Chicago Avenue, Chicago, IL 60611. (312) 440-2660. Fax (312) 440-2824. Summary: This article reports on a prospective, controlled study that was designed to assess the effectiveness of a preventive oral protocol in children receiving antineoplastic treatment for acute lymphoblastic leukemia (ALL). During a 13 month period, 96 children from one to sixteen years of age with a diagnosis of ALL were evaluated. When the study was initiated, 60 patients already undergoing chemotherapy received palliative treatment for complications (Group 1). Thirty-six children (Group II) with newly diagnosed ALL received a daily preventive protocol consisting of elimination of bacterial plaque, application of a mouthwash with a nonalcoholic solution of chlorhexidine 0.12 percent, and topical application of iodopovidone, followed by 'swish and swallow' with nystatin 500,000 units. Children in both groups were examined every 7 to 14 days by the pediatric dentistry team. The authors found a significant improvement in oral hygiene and a significant decrease in the incidence of mucositis grade 2 and oral candidiasis in the Group II children. These findings show that the systematic application of a preventive protocol significantly reduces the incidence of oral complications. The results of the study identify a need to include a pediatric dentist in a multidisciplinary team which provides oral care for cancer patients. 5 tables. 33 references. (AA). ·
Oral Hairy Leukoplakia in a Patient with Acute Lymphocytic Leukemia Source: Oral Diseases. 5(1): 76-79. January 1999. Contact: Available from Stockton Press. Marketing Department, Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom. (800) 747-3187. Summary: This article reports the first case of oral hairy leukoplakia (OHL) in an HIV negative 56 year old patient with acute lymphocytic leukemia (ALL). A white plaque was observed while the patient was in complete remission following chemotherapy scheme. The clinical and histopathologic findings were typical for OHL and the polymerase chain reaction method was positive for Epstein Barr virus DNA. The authors concludes that underdiagnosis and underreporting of OHL in patients with a malignant hematological disease and the apparent different environmental factors to which these non-AIDS patients have been exposed, probably constitute some of the reasons for the very few OHL cases reported in these patients. The patient, after the excisional biopsy, received prophylactic antibiotics and acyclovir and had an uneventful recovery. Careful examination of patients with a malignant hematological disease or other immunodeficiency state is suggested, in order to add knowledge to the biologic mechanisms and behavior of OHL. 3 figures. 30 references.
Federally Funded Research on Leukemia The U.S. Government supports a variety of research studies relating to leukemia. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
6
Leukemia
database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to leukemia. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore leukemia. The following is typical of the type of information found when searching the CRISP database for leukemia: ·
Project Title: A NON MAMMALIAN MODEL FOR HUMAN ALL Principal Investigator & Institution: Walker, Charles W.; Zoology; University of New Hampshire Service Building Durham, Nh 038243585 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 31-MAR-2003 Summary: The investigators take advantage of naturally occurring disease in the softshelled clam Mya arenaria. This leukemia: 1) is fatal; 2) occurs at high frequency in the wild (five-to-sixty percent); 3) is transferable to normal clams and; 4) is remarkably similar to human ALL-L3 (Burkitt's leukemia) in the morphology, behavior and cytochemistry of the leukemia cells, in the structure and expression of the p53 gene and in its response to etoposide. In preparation for this study, we have developed a mass culture system for clam leukemia cells and are the first to clone and determine expression patterns for clam c-ras and p53. Clam p53 has a binding site for MDM2 and its transcriptional activation domain is seventy-three percent conserved compared to human p53 protein. This suggests that downstream genes involved in the cell cycle and in apoptosis should also be transcriptional targets for clam p53. Much remains to be learned about this emerging leukemia model. We will use clam blood to address three specific aims that should expedite our understanding of genes involved in this disease and should help to either further validate or to discount this model. The investigators will: 1) Determine the cytotoxicity for clam leukemia of compounds widely employed in human ALL chemotherapy; 2) Determine the cytotoxicity of novel compounds that target p53 or related molecules involved in the cell cycle and/or apoptosis and; 3) Perform mutational analysis of clam p53, c-ras and c-myc. For the first two of these objectives, high throughput cytotoxicity screening will initially be accomplished using microtiter plates. Compounds that show activity against clam leukemia cells will be further tested using larger scale, parallel in vitro and in vivo clam assays for cell and organism viability, p53 expression and apoptosis. Mutational analysis using mismatch detection should reveal mutations in three genes that often cooperate during transformation inhuman leukemia. Clam leukemia offers significant advantages over currently available models for the following reasons: a) It provides an in vitro and in vivo alternative to the relatively few human leukemia cells lines; b) Populations of leukemic clams are more similar to an outbreeding, human clinical population than are those generated from inbred mouse strains or by intentional exposure to know tumor viruses; c) While existing fly and worm models have versions of some human cancer genes that contain naturally occurring or inducible mutations, resulting tumors characteristically affect embryonic and not adult somatic cells (which do not divide in these organisms) and; d) Clams have highly conserved homologs for human c-ras and p53 genes. Homologs for p53 have not yet been identified in any other non-vertebrate models, including yeast. Data that we generate in this study should point out p53related molecular mechanisms that are held in common with human ALL.
Studies
7
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: AML1 IN NORMAL AND LEUKEMIC CELLS Principal Investigator & Institution: Downing, James R.; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2001; Project Start 01-AUG-1996; Project End 31-MAY-2006 Summary: The AML1/CBFbeta transcription factor complex is one of the most frequent targets of genetic alterations in human acute leukemia, being targeted in up to one-third of acute myeloid and lymphoblastic leukemia by either chromosomal induced rearrangements, or point mutation. Prior work from my laboratory has demonstrated that AMNL1 normally functions as a master regulatory transcriptional switch that is essential for the formation of the definitive hematopoietic systems. In our preliminary data, we now extend this observation to show that AML1/CBFbeta establishes, in a dose-dependent manner, a transcriptional cascade that is required for the formation of definitive hematopoietic stem cells (HSCs) in the aorta-gonad mesonephros region (AGM) of the developing embryo. Moreover, subtle alterations in the level of AML1/CBFbeta induces dramatic changes in the temporal and spatial generation of HSCs, shifting them from their normal position in the AGM to the yolk sac. The initiation of leukemia by chromosomal rearrangement-induced-induced alteration in ABL1/CBFbeta appears to result at least in part, from a partial dominant negative inhibition of normal AML1/CBFbeta, leading to alterations in the self-renewal and maturation of HSCs. Importantly, however, our preliminary data clearly demonstrates that AML1-ETO alone is insufficient to induce leukemia, but rather must cooperate with secondary genetic alterations to transform HSC. Based on these observations, our working hypothesis is that a certain threshold level of AML1/CBFbeta is required for the function of HSC. Genetic changes that decrease the activity of the complex below this level directly alter HSC growth, leading to a pool of "pre-leukemic) cells that must acquire secondary mutations before they can generate a full leukemic phenotype. To directly address this hypothesis, experiments are proposed in Specific Aim 1 that will utilize a conditional AML1-ETO knock in-mouse that was recently generated in my laboratory to define the spectrum of secondary mutations able to cooperate with AML1ETO to induce leukemia. In Specific Aim 2, we will extend these studies to determine how AML1 mutations identified in familial and sporadic cases of AML predispose to leukemia through the generation of mice containing these mutations in their germline. Together these studies should provide critical insights into the molecular pathology of the core-binding factor leukemia. Moreover, the murine models developed through these efforts should prove to be valuable reagents through which to assess the potential therapeutic use of drugs targeted toward either AML1-ETO or its bound nuclear corepressors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: ANTIGEN-PRESENTING FUNCTION OF CD1 MOLECULES Principal Investigator & Institution: Brutkiewicz, Randy R.; Assistant Professor; Microbiology and Immunology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2005 Summary: (provided by applicant): A fundamental understanding of the mechanisms involved in the processing of antigens and their presentation to cells of the immune system is critical to the design of new and more effective treatments against cancer and
8
Leukemia
other diseases. Analyses of antigen processing, presentation and host defense have focused on studying pathways in which proteins are degraded into small peptides that are subsequently presented to the immune system. Recently, a novel pathway for antigen presentation to T cells by the major histocompatibility complex class I-like molecule, CD1, has been identified. CD1 molecules have been shown to present glycolipids, such as those derived from Mycobacterium species, rather than peptides, to T cells. Murine and human CD1d molecules are recognized by a novel subpopulation of T cells called NKT cells. NKT cells produce both Th1 and Th2 cytokines and appear to be important in regulating and/or mediating immune responses to pathogens, as well as to cancer. CD1 molecules are expressed on the surface of hematopoietic cells (e.g., T cells, B cells, macrophages) and are found on a number of T and B cell lymphomas and leukemias. Our hypothesis is that alterations in the natural glycolipid ligands bound to CD1 in hematopoietic tumor cells affect their recognition by NKT cells. To test this hypothesis, the following specific aims are proposed: 1. Assess the role of the intracellular trafficking and cell surface turnover of CD1 molecules in their recognition by NKT cells, 2. Determine the endogenous ligands in representative murine CD1+ T cell lymphoma and B cell leukemia cells, and 3. Analyze the in vitro and in vivo antitumor activity of NKT and NK cells against murine CD1+ hematopoietic tumor cells. Alterations in CD1-bound glycolipid antigens may play important roles in the ability of these tumors to evade the host's antitumor immune response. The proposed studies will also have wide-ranging applications in the development of novel treatments aimed not only at CD1 hematopoietic tumor cells, but also infectious diseases and autoimmunity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: ANTILEUKEMIA ACTIVITY OF PERILLYL ALCOHOL Principal Investigator & Institution: Clark, Steven S.; Human Oncology; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2003 Summary: The Bcr/Abl oncogene encodes a tyrosine kinase that is expressed in leukemias that carry the Philadelphia chromosome translocation (Ph+). The kinase interacts with different cell signaling pathways to cause factor-independent growth, resistance to apoptosis and oncogenic transformation. These pleiotropic activities of Bcr/Abl affect the pathogenesis of Ph+ leukemias by inhibiting the normal rate of cell death and by enabling Ph+ cells to resist conventional chemotherapy that induces apoptosis in other leukemias. A central hypothesis of this proposal is that inhibition of signaling pathways downstream of the Bcr/Abl kinase should render leukemia cells dependent on growth factors and sensitive to apoptosis. Perillyl alcohol (POH) belongs to a new family of chemotherapy agents and has shown excellent therapeutic rations in rodent carcinoma models. The range of potential anti-tumor activities of POH overlaps with some signaling pathways that are affected by the Bcr/Abl kinase. Thus, POH is a logical compound to test for anti- leukemia activity in Bcr/Abl-induced leukemia. Preliminary experiments demonstrated that in Bcr/Abl-transformed cells, POH rapidly induced G1 arrest and apoptosis. In contrast, Bcr/Abl- transformed cells were resistant to apoptosis induced by different conventional chemotherapy agents. This anti-leukemia activity of POH closely correlated with inhibition of the Raf-ERK signaling pathway downstream of Bcl/Abl. On the other hand, POH treatment did not affect other Bcr/Abl signals that are responsible for maintaining expression of c- Myc. Normally, expression of c-Myc is cell cycle regulated, however, when c-Myc expression is enforced during G1 arrest, cells undergo apoptosis. Therefore, POH may uncouple a Bcr/Abl signaling
Studies
9
pathway through Raf that is necessary for maintaining cell growth, while not affecting other Bcr/Abl signals that induce constitutive c-Myc expression. This combination may lead to apoptosis in leukemia cells. This model will be evaluated further by examining 1) the role of the Bcr/Abl oncogene in sensitizing cells to POH, 2) how POH affects signaling through Raf, and 3) whether POH induces Myc-dependent apoptosis in leukemia cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: APE CHEMO/RADIOTHERAPY
EXPRESSION/LEUKEMIA
RESPONSE
TO
Principal Investigator & Institution: Robertson, Kent A.; Associate Professor of Pediatrics; Pediatrics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2001; Project Start 01-AUG-1998; Project End 31-MAY-2003 Summary: DNA damage in the form of apurinic/apyrimidinic (AP) sites is induced by cytotoxic agents resulting in base substitution mutations and blocks to DNA replication. The DNA base excision repair (BER) enzyme, AP endonuclease (APE), is a multifunctional protein involved in DNA base excision repair, oxidative signaling, transcription factor regulation, cell cycle control, and apoptosis. APE is essential for the repair of AP sites thus maintaining cellular and genetic integrity. Deficient expression of APE results in a heightened sensitivity to radiation and alkylating agents with resultant tissue damage. Logically it follows that APE may also play a role in the sensitivity to malignant cells to DNA damaging therapeutic agents. Many cancer therapeutic agents will induce apoptosis or programmed cell death, however little is known about the relationship of DNA repair enzymes (particularly BER) and apoptosis. Preliminary observations indicating that APE expression can be suppressed in myeloid leukemia cells by retinoic acid or DMSO while inducing apoptosis, has led to the hypothesis that: Decreased expression of APE is functionally related to apoptosis in myeloid leukemia cells. The specific aims are: Specific Aim #1 What is the relationship of APE expression to myeloid leukemia cell differentiation and apoptosis? Specific Aim 2: What is the role of APE protein phosphorylation in APE expression, function and apoptosis. Specific Aim #3: Determination of the molecular mechanisms that are responsible for downregulation of APE expression upon induction of apoptosis. We propose to initiate studies on the relationship of APE expression and phosphorylation to cell differentiation, apoptosis, and sensitivity to cytotoxic agents, with the long-term goal of developing ways to enhance the chemo/radio sensitivity of leukemia cells by manipulating expression of APE. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: ARSENIC BASED THERAPY OF BCR ABL POSITIVE LEUKEMIAS Principal Investigator & Institution: Bhalla, Kapil N.; Professor of Medicine; Moffitt Cancer Center; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 31-MAY-2004 Summary: The leukemic clone in virtually all of the patients with chronic myeloid leukemia with blast crisis (CML-BC) and approximately one-third of the adults with acute lymphoblastic leukemia (ALL) expresses the bcr-abl fusion gene encoded p210 and p185 Bcr-Abl tyrosine kinase (TK), respectively. Although the chemotherapeutic regimens or bone marrow stem cell transplantation employed against acute leukemias can also produce complete remissions in Bcr-Abl positive ALL and CML-BC, these
10 Leukemia
remissions are not durable and the overall clinical outcome remains dismal. This creates a strong rationale to test novel strategies in this clinical setting. Arsenic Trioxide (As2O3 or AT) is clinically active against relapsed or refractory acute promyelocytic leukemia (APL), where it downregulates the levels of the fusion protein PML-RARdelta causing partial differentiation and apoptosis of APL cells. Recently, we have demonstrated that clinically achievable levels of AT can also reduce p210 or p185 Bcr-Abl fusion protein levels and induce apoptosis of CML-BC cells. Based on these findings, we propose to conduct a Phase II clinical-pharmacologic trial of AT (NCI/CTEP sponsored) as the induction therapy for relapsed and refractory; Bcr-Abl positive adult ALL and CML-BC. In vitro studies on the patient derived leukemic blasts are proposed to determine the molecular correlates of the clinical response and apoptosis induced by AT. We have also shown that STI571, a relatively specific inhibitor of Bcr-Abl TK activity, induces differentiation and apoptosis of Bcr-Abl positive leukemic cells. Therefore, we also propose to investigate the in vitro apoptotic and differentiation effects of a combination of AT and STI571 in Bcr-Abl positive leukemic blasts. The specific aims of this proposal are: AIM 1: To determine the clinical efficacy, i.e., the rate and duration of clinical and hematologic response and overall survival, secondary to treatment with daily intravenous AT in adult patients with Philadelphia chromosome (bcr-abl fusion gene) positive relapsed or refractory ALL or CML-BC. AIM 2: To determine the pharmacokinetic parameters of AT, i.e., AUC and Css and correlate these with the clinical and cytogenetic response in patients with Bcr-Abl positive ALL or CMLBC. AIM 3: To correlate the clinical response to AT with the decline in the bcr-abl mRNA levels determined by real-time RT-PCR. AIM 4: To correlate the clinical and in vivo molecular response to AT with AT-induced in vitro downregulation of Bcr-Abl and Akt protein levels, histone hyperacetylation as well as differentiation and apoptosis, utilizing the pre-treatment samples of leukemic blasts. AIM 5: To determine the in vitro differentiation and apoptotic effects of STI-571 alone and in combination with AT in the pre-treatment samples of Bcr-Abl positive leukemic blasts. These in vitro and in vivo studies are designed to evaluate AT-based novel strategies against Bcr-Abl positive human leukemias. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: BENZODIAZEPINE RECEPTOR AND DRUG RESISTANCE IN AML Principal Investigator & Institution: Banker, Deborah E.; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2003 Summary: We are investigating molecular bases of drug resistance as markers of clinical outcome in acute myeloid leukemia (AML) and testing various drug-sensitizing strategies in hopes of improving cure rates for patients with this disease. Relevant chemotherapeutics induce apoptosis and leukemic blasts become drug resistant by downregulating apoptotic responses to these drugs. As a result of anti-apoptotic activities, expression of Bcl-2 family proteins is associated with failure to achieve remission, with short disease-free survival, and with drug-resistant relapse in AML. Bcl2 proteins are constituents of mitochondrial pore complexes (PTPC) where they block apoptosis by antagonizing mitochondrial pore dissolution that otherwise occurs after lytotoxic treatments. Like Bcl-2, peripheral benzodiazepine receptors (pBzR) reside in PTPC of normal and leukemic blood cells and can protect transfected leukemia cells from apoptosis. However, the association of pBzR expression with clinical outcome has not been directly tested. If high pBzR expression predicts clinical failures in AML, pBzR would be a rational target for molecular anti-leukemia therapies. PK11195 is a high-
Studies
11
affinity pBzR antagonist that can block the PTPC protection afforded by Bcl-2 proteins, and can thereby overcome drug resistance. However, whether pBzR or Bcl-2 expresson levels determine the efficacy of PK11195 is unknown. We propose laboratory analyses that will determine the variability of BzR expression in a large number of cell samples collected from AML patients in IRB-approved clinical trials from which complete clinical data is available. We will use standard statistical analyses to determine whether pBzR is an independent prognostic marker in AML. We also propose laboratory analyses of PK11195 efficacy in primary AML cell samples treated with different relevant drugs and in isogenic cell lines over-expressing different anti-apoptotic proteins. NOD/SCID mice will be used as an in vivo model to further test PK11195 efficacy in sensitizing engrafted AML cells. In vitro analyses of normal bone marrow samples and of non-leukemia cells in engrafted mice will examine possible PK11195 toxicities: Data collected in these studies will improve our understanding of the molecular bases of drug resistance in AML. Furthermore, if drug-sensitizing by PK11195 is documented and low toxicity is confirmed in these experiments, novel treatment strategies that include PK11195 will be warranted for AML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: BIOCHEMICAL STRATEGIES TO INCREASE LEUKEMIA RESPONSE Principal Investigator & Institution: Gandhi, Varsha; Associate Professor; Clinical Investigation; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 15-SEP-1992; Project End 31-JUL-2006 Summary: (provided by applicant): This proposal is an extension of CA57629 that has been focused on understanding the metabolism, mechanism of action, and interaction of nucleoside analogs. With the success rate of analogs in leukemias, several laboratories including ours have investigated the mechanisms of cell death by these agents. The steps include formation of triphosphate of the analog, incorporation into replicating DNA, inhibition of ribonucleotide reductase (with newer analogs) and finally inhibition of DNA synthesis. Continued inhibition of DNA synthesis proceeds to cell death through apoptosis. When tested in cell lines, which are actively cycling and replicating DNA, such scenario seems to be in place. However, when one tries to validate this process during therapy, the outcome is conflicting and intriguing. The biology of leukemia cells in the body is very different from cell lines in culture. Leukemia cells in peripheral blood are generally non- or slow- cycling and with a very small percent of cells in S-phase (0-5%). Nonetheless after 5-days of effective nucleoside analog therapy, there is a massive cytoreduction (1 to 3-log decrease). Our hypothesis is built around these premises to suggest that in addition to conventional S-phase mediated pathway, there may he additional pathways that result in non-S-phase cell death during therapy. To test this hypothesis, we want to pursue three specific aims that are focused toward different mode of cell death by analogs. First, we plan to define the elements of cell death caused by conventional DNA synthesis inhibition pathway during therapy. Using nelarabine and clofarabine, two of the most successful new nucleoside analogs in the clinic, we plan to investigate the role of cellular pharmacokinetics and cellular pharmacodynamics in cell death. These parameters will be compared with clinical response to these therapies. Second, we plan to identify mitochondria induced cell death of leukemia cells during therapy. Nucleoside analogs may affect mitochondria directly and/or indirectly to induce cell death in circulating leukemia cells during therapy. Direct effect such as mitochondrial respiratory function involving ATP synthase, adenosine nucleotide translocator (ANT), and early decrease in mitochondnal
12 Leukemia
membrane potential will be accessed to elucidate the role of mitochondria induced apoptosis. Indirect effect will include release of cytochrome c, and late effect on membrane potential. Finally, we will investigate the role of receptor-mediated cell death of leukemia cells during therapy. Following our lead in cell lines that analog incorporation results in induction of fas ligand followed by fas-mediated cell death of non-Sphase population, we plan to pursue the role of fas in cell death during therapy. We feel that knowledge gained through these aims will assist us in designing optimal therapy of leukemia with nucleoside analogs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: BIOMARKERS OF TREATMENT RELATED LEUKEMIA Principal Investigator & Institution: Felix, Carolyn A.; Associate Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2005 Summary: (Adapted from the investigator's abstract) The objective of this work is to develop new avenues to identify undergoing anticancer therapy who are at increased risk of leukemia as a treatment complication and to facilitate detection of the leukemic clone earlier in the course of the disease. For children with metastatic neuroblastoma receiving N6 therapy, the incidence of leukemia is 7%. About 40% of cases are related to alkylating agent therapy and have chromosome 5 and/or 7 loss; about 40% have translocation of the MLL gene at chromosome band 11q23, which occurs in leukemias related to DNA topoisomerase II inhibitors. Because of its efficacy against neuroblastoma, N6 therapy will be incorporated into the high-risk neuroblastoma trial for the Children's Cancer Group. Etoposide, doxorubicin and cyclophosphamide used in N6 therapy are metabolized by cytochrome P-450 (CYP) 3A; all are associated with leukemia as a treatment complication. The metabolites have genotoxic properties that may be relevant to leukemogenesis. The promoter of the CYP3A4 gene is polymorphic. Prior studies showed that the CYP3A4 wild-type genotype increased and CYP3A4 variant genotypes decrease the risk of treatment-related leukemia with MLL gene translocations. Prior studies also showed that the MLL gene translocation can be present early in the course therapy at how cumulative doses of DNA topoisomerase II inhibitors. MLL presents an extreme example of a translocation involving many partner genes; Southern blot analysis and cDNA panhandle PCR are two methods that can track the translocations in preleukemic samples regardless of the partner gene. They hypothesize that CYP3A4 genotype and MLL gene translocations are relevant biomarkers for treatment-related leukemia. The plans of the cooperative group to use N6 therapy not only mandate systematic investigation of who is most at risk, but also provide a unique clinical opportunity to examine CYP3A4 genotype and MLL gene translocations as a relevant biomarkders in the context of the therapeutic trial. The purpose of aim 1 is to validate the association of CYP3A4 genotype with treatmentrelated leukemia. The purpose of aims 2 and 3 is to determine and compare the utility of MLL gene translocations, detected by Southern blot analysis and cDNA panhandle PCR, as leukemia-specific markers that predict development of disease. The purpose of aim 4 is to explore the baseline frequency of MLL gene translocations in untreated pediatric patients diagnosed with neuroblastoma and to determine how chemotherapy affects this frequency during the course of treatment. Risk factors for treatment-related leukemia are poorly understood. Predictive biomarker assays will enable rational modifications of primary cancer therapies and provide new opportunities for early intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
13
Project Title: BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA Principal Investigator & Institution: Bennett, Michael; Professor of Pathology; Pathology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from the investigator's abstract) NK cells are cytolytic for tumor cells but clinical use of autologous NK cell treatment has been relatively unsuccessful. A major potential cause for this is that NK cells have receptors for 'self' class I transplantation antigens, and the majority of these receptors respond by sending negative signals that prevent NK cell lysis. This explains why NK cells preferentially lyse HLA or H2 allogeneic, or class I deficient target cells. During the first 3 years of this project, the investigators have obtained evidence that blocking negative signals for two inhibitory receptors, Ly-49I and C, with F(ab')2 5E6 MAbs enhanced survival of B6 mice infused with syngeneic C1498 myeloid leukemia cells. Use of T and B cell deficient mice indicated that NK cells were the effectors. The same treatment did not inhibit growth of syngeneic BMC in irradiated B6 mice (a safety concern) but did enhance the ability of mice to reject allogeneic BMC grafts. A new 8H7 anti-Ly-49I MAb at low doses blocks negative signals without depleting NK cells and can be used as a reagent with a longer half-life than MAb fragment. The F(ab')2 reagent is limited in function due to short halflife in serum (<18h). This renewal application has 5 specific aims: Aim 1. Generate more effective MAb reagents to block negative signals to NK cells without depleting them the investigators have mutated the Fc region of 5E6 MAb to remove a critical Ncarbohydrate attachment site that is required for the MAbs to deplete cells in vivo. Generate similar reagents against Ly-49G2, an inhibitory receptor expressed on a large fraction of murine NK cells.Aim 2. Develop rapid assays for growth assessment of leukemia cells in vivo to quicken the pace of developing new reagents, e.g., infusion of leukemic cells i.v. into irradiated hosts, and assessing proliferation 5 days later by measuring DNA synthesis, an assay for proliferating cells. Use 123I-iododeoxyuridine to label proliferating cells that can be used for imaging of growing tumors and for labeling leukemia cells that are infused so that survival can be determined by whole body counting. Aim 3. Test the reagents for the ability to 'purge' leukemia cells from syngeneic marrow cells 'spiked' with different numbers of leukemia cells.Aim 4. Expand the clinical treatment protocol to include supplemental treatment of mice with IL-2 after the infusion of syngeneic or allogeneic IL-2 activated NK cells coated with anti-5E5 and/or anti-Ly49G2 F(ab')2 MAbs. Aim 5. Extend the studies to the use of human myeloid leukemia cells, human NK cells, and immunodeficient SCID mice pretreated with asialo GM1 or SCID-NOD mice, which accept grafts of human leukemia cells. Non-depleting MAbs or fragments to human negative signaling receptors for class I antigens expressed on the leukemia cells will be tested for anti-leukemia effects. Success with these studies will hopefully determine if this approach has potential for clinical application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: BRAIN NEOPLASMS, LEUKEMIA & PETROCHEMAL EXPOSURES Principal Investigator & Institution: Christiani, David C.; Professor; Environmental Health; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 15-AUG-2000; Project End 31-JUL-2005
14 Leukemia
Summary: (Adapted from the Applicant's Abstract): Brain tumors and leukemia are the most common children and adolescent malignancies in the U.S. Adequate information on the role of inherited genetic susceptibility and environmental exposures in the development of neoplasms in children and adolescents is lacking. In Taiwan, four large petrochemical industries are located in Kaohsiung metropolitan area. These facilities are proximal to residential areas because of the high population density in the region. Data have shown that the concentrations of ambient polycyclic aromatic hydrocarbons (PAH) and volatile organic compounds (VOC) around the petrochemical industries are at least 10 and 2 times, respectively, higher than those in U.S. industrialized communities. Our preliminary case-control study in Kaohsiung metropolitan showed that young residents (< 30 yr) living within 3 kilometers (km) of the vicinity of petrochemical industries have a 6.0 fold increase in brain neoplasms and a 2.9 fold increase in leukemia. The purpose of this proposal is to examine the association of exposure to air contaminants (PAH & VOC) emitted from the petrochemical industries, specific genetic polymorphisms (P4501A1 (MspI & exon 7) and GSTMI & Tl) from study subjects and their parents, and the risks of brain tumors and leukemia among children and youths in metropolitan Kaohsiung. Our hypothesis is that there is an increase risk of brain tumors and leukemia in patients with higher cumulative exposure to these hazards, and that heritable polymorphisms in several genes modify this association. In addition to an independent association of environmental and genetic factors with brain neoplasm and leukemia, we hypothesize that there is greater risk associated with the presence of combined environmental exposure and the high risk genotype. We also assess the role of the parental genetic polymorphisms in the development of cancer in their sibling. This proposed study uses an environmental molecular epidemiologic approach, utilizing prospective enrollment of a cohort of brain tumor and leukemia subjects and a population-based case-control design. This proposal is responsive to the recommendation of the National Research Council that risk assessment and public health policy pay special attention to the protection of children. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CANCER AND LEUKEMIA GROUP B Principal Investigator & Institution: Canellos, George P.; Chief; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-APR-1982; Project End 31-MAR-2009 Summary: (provided by applicant): The Dana-Farber Cancer Institute (DFCI) and DanaFarber/Partners CancerCare (DF/PCC) proposes to use its membership in the Cancer and Leukemia Group B (CALGB) to support participation in therapeutic research and other clinical trials, both in the Institute and its affiliate institutions. The goals of this project will be the initiation and participation in Phase I, II and III cooperative clinical trials involving chemotherapy, surgery and radiation therapy. A major emphasis will be made in developing new therapeutic strategies both at the DFCI and MGH, and in pilot collaborative investigations with interested members of CALGB. Dana-Farber investigators would continue to be actively involved in disease and modality committees of the CALGB. This project is designed to bring cooperative group trials to regional community hospitals affiliated through the Dana-Farber Cancer Institute throughout New England and to Puerto Rico through its affiliation with the University of Puerto Rico Oncology program. The Dana-Farber Cancer Institute has a broad program of Phase I trials of new treatments including biologics. The extensive involvement of members of the faculty of Dana-Farber/Partners Cancer Care in CALGB facilitates the transmission of Phase I observations and ideas into broader Phase II or
Studies
15
even Phase III trials. To that end our investigators have assumed leadership roles in the modality/disease committees of CALGB (GI, Leukemia, Lymphoma, Breast, GU, Correlative Sciences, Melanoma, Clinical Economics for example). Our objectives on this grant is to increase accrual through our expanded network, which now includes Hartford Hospital (with 900 beds), and to increase interests of young investigators at DF/PCC in participation in CALGB at the administrative and scientific levels. The basic scientific efforts of the Dana-Farber/Harvard Cancer Center will be, where possible, brought to the correlative science program of CALGB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CANCER AND LEUKEMIA GROUP B Principal Investigator & Institution: Hurd, David D.; Internal Medicine; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2001; Project Start 01-APR-1979; Project End 31-MAR-2003 Summary: (adapted from the applicant's abstract): The Comprehensive Cancer Center of Wake Forest University continues to be a major accrue to Cancer and Leukemia Group B protocols. A modest decrease in accrual is noted for 1996 which reflects economic constraints and the influence of managed care. We have obtained an R13 CA-74441 demonstration grant to evaluate and strengthen the recruitment and retention of minorities in cancer clinical trials. Further, we are applying through CALGB for the minority initiative program to obtain data management support for East Carolina University. They have access to a large minority population in eastern North Carolina. The anticipation that first-line protocols for leukemia, lymphoma, and advanced breast cancer will soon be available should also strengthen our accrual in this grant period. Our institutional and CCOP accrual to protocol #9399 (chemotherapy prevention of prostate cancer with finasteride) is an expression of our ability to accrue large number of patients quickly to cancer control clinical trials. Dr. David Hurd, Chair of the Transplant committee and Dr. Electra Paskett, Chair of the Cancer Control committee provide strong scientific contributions to CALGB and further strengthen our accrual to clinical trials. Dr. Jim Atkins, Chairman of the Southeast Cancer Control Consortium (SCCC), is developing a strong regional program with increasing emphasis on the accrual of minorities to clinical trials. Our strong community outreach clinical trials program is focused to develop community techniques which will improve accrual to clinical trials. The development of multi-disciplinary affinity groups in breast, GI, GU, leukemia, lung, neuro-oncology, and oral head/neck cancer will also strengthen our institutional contributions to Cancer and Leukemia Group B. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: CANCER AND LEUKEMIA GROUP B Principal Investigator & Institution: Edelman, Martin J.; Director; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 01-APR-1982; Project End 31-MAR-2003 Summary: The GCC continues to grow and develop a scientific and clinical relationship with CALGB. A number of the faculty at GCC participate in CALGB scientific and administrative committees. GCC faculty design, conduct and chair many group studies and enter large numbers of patients onto CALGB studies. The GCC faculty are on five core committees and chair the Leukemia Committee and the Subcommittee on Thoracic Surgery. The funding to continue these activities will allow further growth in the scientific and administrative participation of GCC and its affiliates. GCC is one of the
16 Leukemia
largest accruing institutions for leukemia and one of the largest accruing institutions overall. The basic science laboratories studying acute leukemia, cellular, animal and clinical pharmacology and cellular and molecular biology form an important correlative science resource for the group. The grant will allow GCC to continue its highly effective scientific and administrative participation in the group and will continue to allow them to develop a scientific base in the greater Baltimore area and across the state and region. The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CANCER AND LEUKEMIA GROUP B CCOP RESEARCH BASE Principal Investigator & Institution: Schilsky, Richard L.; Associate Dean for Clinical Research; Cancer Research Facility; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2001; Project Start 30-SEP-1983; Project End 31-MAY-2004 Summary: This application is submitted by the Cancer And Leukemia Group B (CALGB) to begin its sixteenth year as a primary multi-modality Research Base for seven Community Clinical Oncology Programs (CCOPs) and two Minority-Based CCOPs. CALGB is a Clinical Cooperative Group with 30 Main Member institutions and a membership of about 3000 health professionals at about 200 hospitals, clinics and physicians' offices. The overall objective is to provide an organized and collegial environment for community based health care professionals to interact with their academic counter-parts in the development and implementation of cancer prevention and control research studies and the latest cancer treatment clinical trials. CALGB proposes to enhance the translation of new information from a strong basic correlative sciences program in cancer treatment to an evolving strong program in cancer prevention and control research. Major themes are chemoprevention, intermediate markers and quality of life research. Strategies will be developed to assist CCOPs to increase accrual of minorities, women and other underserved people into ethical, high quality clinical trials which will result in a decrease in cancer incidence, morbidity and mortality. A special focus has emerged in cancer in the elderly and a new committee is charged with developing research studies of particular relevance to this rapidly growing segment of the population. CCOPs will be assisted in broadening their networks to include more primary health professionals and specialists to help in the diffusion of state-of-the-art cancer care at the community level. There are seven cancer site committees (Breast, Gastrointestinal, Leukemia, Lymphoma, Melanoma, Prostate and Respiratory) which work closely with thirteen modality committees (Pharmacology and Experimental Therapeutics, Correlative Sciences- Leukemia/Lymphoma, Correlative Sciences-Solid Tumors, Transplant, Pathology, Surgery, Radiation Oncology, PsychoOncology, Cancer Control, Oncology Nursing, Patient Issues, Clinical Research Associates, Cancer in the Elderly) to plan and implement cancer prevention and treatment studies using the latest technologies and information available. This project will bring these advances to the community hospital level where CCOP trained health care providers can apply them immediately. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
17
Project Title: CANCER AND LEUKEMIA GROUP B-LEUKEMIA CORRELATIVE SCIENCE Principal Investigator & Institution: Caligiuri, Michael A.; Professor and Director; Comprehensive Cancer Center; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: The Cancer and Leukemia Group B (CALGB) Leukemia Correlative Sciences Program has worked to attain a highly successful integration of correlative laboratory studies into the design and implementation of CALGB leukemia trials. Dr. Michael A. Caligiuri assumed leadership of the CALGB Leukemia Correlative Science Committee (LCSC) in August of 1999 following 18 years of Committee leadership by Dr. Clara Bloomfield. The LCSC has been restructured and refocused entirely on leukemia, moving evermore into the molecular age of diagnostics, pathogenesis, and treatment. The goal is to use cytogenetics, immunology, and molecular biology to better understand the heterogeneity of leukemia with regard to diagnosis, prognosis, and ultimately treatment. In this competitive renewal application, we have assembled three Cores (Cytogenetics, Banking, and Administration) and six Projects, each of which is utilizing materials collected from patients treated on CALGB leukemia treatment protocols in order to address a scientific question and correlate it with disease outcome. Having set into motion a paradigm for stratification of leukemia treatment based on risk of relapse during this last funding cycle, the current CALGB Leukemia Correlative Science application will attempt to dissect out additional leukemia patients that can be predicted to do well or do poorly in response to standard or novel therapies, and to then work with the CALGB Leukemia disease committee to stratify their treatment based on risk. In this way, we hope to significantly impact on the cure rate of leukemia over the next six years of funding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: CHARACTERIZATION OF HUMAN LEUKEMIC STEM CELLS Principal Investigator & Institution: Bonnet, Dominique A.; Assistant Professor/Chief; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 01-JUN-2000; Project End 31-MAY-2004 Summary: Understanding the processes that regulate the developmental program of normal stem cells and how aberrations in this program initiate leukemic proliferation remain a major challenge in biology. Progress to address these major questions in the human hematopoietic system has been hampered, until recently, by the lack of in vivo assays for normal and leukemic stem cells. The only way to conclusively assay stem cells is to follow their repopulating capacity. The recent development of methods to transplant human hematopoietic cells into immune-deficient mice provides an important approach to characterize stem cells and to develop animal models for hematopoietic diseases including leukemia. The development of an in vivo model that replicates many aspects of human AML and allows the identification of a novel leukemic stem cell (termed the SCID-Leukemia Initiating Cell, SL-IC) based on the ability of that cell to initiate AML in NOD/SCID mice provides the foundation of an assay to define the biological and molecular properties of such new leukemic stem cells. The major long-term objectives of my research program are to further characterize human leukemic stem cells. The research project proposed here will focus on three objectives: 1) determine the existence of an heterogeneity at the leukemic stem cell level (both Lin-CD34+ and Lin-CD341o/- subfractions have leukemic stem cell properties); 2)
18 Leukemia
evaluate the biological properties of the leukemic stem cell pool (i.e., self-renewal, proliferation and differentiation capacities, response to cytokines and/or stromal cell environment); 3) to study the gene expression pattern of six regulatory molecules (AML1, PU.1, GATA- 1, Hox A5, Hox B4 and SCL/tal-1), known to be involved in the early stage of hematopoietic development and/or in the physiopathology of leukemia, before and after induction of differentiation of the leukemic stem cell fraction. The information obtained from these studies will gave us a more complete understanding of the nature of the leukemic stem cells, their biological properties, and the early molecular factors involved in the maintenance and/or differentiation of such leukemic stem cells. Furthermore, the knowledge gained about leukemic stem cells will allow us to devise new therapeutic strategies such as cell purging strategy, gene suicide therapy, antisense therapy and others, targeted specifically to the leukemic stem cell pool. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CHILDHOOD LEUKEMIA AND ENVIRONMENTAL EXPOSURES Principal Investigator & Institution: Buffler, Patricia A.; Professor of Epidemiology; None; University of California Berkeley Berkeley, Ca 94720 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: The causes of childhood leukemia remain largely unknown. The purpose of this proposal is to expand an existing case-control study of molecular of childhood leukemia in size and geographic region and refine the measurement of exposure to household chemicals and pesticides, and to assess exposure to electric and magnetic fields. The temporal relationship of exposure to environmental agents including dietary, occupational and residential chemical exposures are determined by use of self-report and interview data. Molecular biologic techniques are used to characterize the subtypes of leukemia and the presence of genetic changes. Biological specimens include bone marrow and peripheral blood of newly diagnosed cases, buccal cell specimens from cases, their mothers and control subjects, and archived newborn blood from cases and controls born in California will be used in the endeavor to identify the timing of exposures. Household pesticides are an environmental exposure of particular concern since previous studies have suggested that chemical and pesticide exposure during pregnancy and after birth may be related to the subsequent development of childhood leukemia. This research will expand a currently funded study of childhood leukemia which includes newly diagnosed cases ages 0-14 which present at four Bay Area referral hospitals during the period 1995-1998. This proposal will double the expected sample size to 400 cases by including cases ascertained at these hospitals an additional three years and expanding the study to include patients from the three major clinical centers for the central valleys of California for four years. Two matched control groups will be obtained for each case: friend controls and birth certificate controls. Friend controls will be randomly chosen from nominees provided by parents that match the case on age, sex, gender, county of residence at diagnosis, and ethnicity of mother. Birth certificate controls will be chosen from California births that match the case with respect to age, sex, gender, county of residence at birth, and ethnicity. A self-administered questionnaire and personal interview will be obtained to collect data related to a spectrum of environmental exposures and other risk factors including dietary history and residential history and history of chemical exposures of the mother prior to and during pregnancy and the child, occupational history and reproductive history of the mother, and health history of the child. A subsequent exposure component will focus on exposures to household pesticides during the past year and during pregnancy and the first two years of the child's life and measure electric and, magnetic fields directly in the
Studies
19
home and indirectly by trained staff coding residential wiring configurations. Molecular characterization of leukemia cases allows for the subclassification of leukemias on a biological basis, and will facilitate the linkage of exposures with leukemia subtypes in the analysis. The proposed study, which will attempt to link specific chemical components with genetic changes found in childhood leukemia, will help to reduce the percentage of leukemias for which there is no known cause. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: COOPERATING GENETIC EVENTS IN MYELOID LEUKEMIA DEVELOPME Principal Investigator & Institution: Largaespada, David A.; Associate Professor; None; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2003 Summary: (adapted from the investigator's abstract) Cancer develops as a result of the accumulation of multiple genetic changes in somatic cells, all of which cooperate in inducing the transformed phenotype. In acute myeloid leukemia (AML) the number and nature of these "cooperating" oncogenic mutations is most often unknown. The BXH-2 mouse offers a model system ideal for the elucidation of interacting gene mutations. In this model, a Murine Leukemia Virus (MuLV) induces AML by acting as an insertional mutagen. The number of different gene whose expression is altered by proviral insertion and which contribute to leukemia development in BXH-2 mice is likely to be large. At least eight different loci have been identified which are mutated by proviral insertion in multiple BXH-2 leukemias, but none of these loci is involved in more than 15% of the leukemias. Therefore, new and more efficient methods for identifying and cloning these cancer genes have been developed. These techniques include the selection of tumor-specific, somatically-acquired proviruses near CpG islands, which greatly enriches for proviruses near genes involved in leukemogenesis, and the development of a highly efficient inverse PCR-based approach for cloning proviral insertion sites. The combination of these two technologies allows rapid progress toward the goal of understanding the complex network of genes mutated during myeloid leukemia development. These procedures have been used to identify mutations in two genes likely to impact the same cell signaling pathway: Nf1 and Cdc251. It is the goal of this proposal to define the overlap between the oncogenic effects of these mutations and discover other proteins involved in this pathway. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: CORE--CLINICAL RESEARCH SUPPORT COMPONENT Principal Investigator & Institution: Stone, Richard M.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-MAR-2003 Summary: (provided by applicant): The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with myeloid malignancies including acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. To achieve this objective, tumor cells and other relevant clinical samples from patients will be collected, catalogued, and distributed to the relevant projects for analysis of the expected therapeutic targets and other molecules that might be important in prognosis or pathophysiology. Secondly, a clinical infrastructure is required to carry out the clinical trials described in Project 5 and additional clinical studies that will emanate from the developmental approaches
20 Leukemia
outlined in Projects 1, 8, 9 & 10. Clinical Research Core resources are required to carry out these functions which extend beyond direct patient care and the clinical laboratory. Without the clinical research support provided in the Core it would be impossible to coordinate the proper collection of multiple research specimens, the adherence to novel complex therapeutic schedules and timely follow-up of patients enrolled on research studies. Also critical to this success of the project is the collaboration of individuals in the Core with the staff from the Biostatistics Core who will provide a quality control system for specimen tracking, computerized data entry, quality of control data and will assist in the design and analysis of the clinical research protocols. The purpose of the Clinical Research Support Core is to provide the following services that will be utilized by all the clinical research studies: 1. To collect research specimens and coordinate patient follow-up at Dana- Farber Partners Cancer Center and collaborating institutions. 2. To act as liaison with outside physicians, hospitals, and biotechnology companies to coordinate the collection of research specimens and follow-up data. 3. To insure that study parameters are followed, ancillary specimens are collected on time and processed properly, confirm eligibility, and patient registration. 4. To insure the accuracy of submitted data from outside sources. 5. To provide data management for the collection of individual patient information. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CORE--CYTOGENETICS FACILITY Principal Investigator & Institution: Bloomfield, Clara D.; Director; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: (provided by applicant): The CALGB Cytogenetic Core provides the infrastructure for giving CALGB investigators high quality cytogenetic data in AML, ALL, MDS, CML and CLL. These data are used in the group for 3 general purposes: a) to answer specific questions regarding the clinical and biologic significance of specific cytogenetic findings in these diseases; b) to provide information required to select the correct treatment study or protocol arm, and to allow appropriate analysis of therapy being investigated; and c) to provide information required for molecular genetic studies described elsewhere in this grant application (e.g., projects 1, 2, 3, and 5). As a result of information discovered (via CALGB protocol 8461) regarding the clinical significance of cytogenetics in AML and ALL, cytogenetics are currently used in stratifying patients for specific arms on our current front-line AML protocol in adults under the age of 60 years (CALGB 19808), and for selecting appropriate protocols for adults with ALL which differ based on cytogenetic findings (CALGB 10001, 10002, 10102). In CML (CALGB 10107) and MDS (CALGB 10105) disappearance of the cytogenetic abnormality will be used for monitoring outcome. Additionally, the integral relationship of cytogenetics with other leukemia correlative science studies (e.g., CALGB 9760, 9862, 20201, 20202) and most of the molecular studies performed through the CALGB Leukemia Tissue Bank (CALGB 9665) mechanism (see Core B of this grant application) make cytogenetic studies an essential component of almost all currently planned leukemia research. Cytogenetic data for AML, ALL and MDS are obtained via CALGB 8461, for CML via CALGB 29801 and for CLL via CALGB 20106 and 20203. The processing of submitted karyotypes and fluorescence in situ hybridization (FISH) results, cytogenetic data management and central review for these studies are done at The Ohio State University (OSU) under the direction of Dr. Clara D. Bloomfield. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
21
Project Title: CYTOKINE GENE THERAPY OF RESIDUAL LEUKEMIA Principal Investigator & Institution: Gautam, Subhash C.; Internal Medicine; Case Western Reserve Univ-Henry Ford Hsc Research Administraion Cfp-046 Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: (Applicant's Abstract) Our long-term goal is to develop novel biotherapies that will specifically target and destroy residual leukemia. The proposed studies will test the general hypothesis that site-directed gene therapy with hematopoietic progenitor cells, genetically modified to secrete human tumor necrosis factor-alpha (hTNF-a), will significantly increase the destruction of leukemia cells remaining after high-dose chemotherapy/bone marrow (BM) transplantation. Our preliminary data show that administration of hTNF-a secreting progenitor cells following chemotherapy with cyclophosphamide (CY) and BM transplantation dramatically enhances survival (80 percent) of mice inoculated with a lethal dose of 32Dp210 murine myeloid leukemia cells without toxic side effects. We will test the hypothesis that combined therapy with CY, BM-transplant, and TNF-a secreting progenitor cells generates a greater antileukemic effect than is produced by any modality alone. We will accomplish this by the following specific aims: 1) determine the extent to which immunomodulatory effects of CY on T-helper (Th) cells and cytotoxic effector cells (CTLs and NK cells) contribute toward the antileukemic activity of CY/TNF-a gene therapy, 2) identify the cell population(s) within BM-transplant (e.g., T cells, mesenchymal cells or progenitor cells) that enhances the efficacy of combined therapy, and 3) determine whether the mechanism(s) of the antileukemic effect of CY/TNF-a treatment involves: a) augmentation of leukemia antigen presentation by dendritic cells, b) generation of leukemia specific (CTLs) and non-specific (NK cells/macrophages) cytotoxic effector cells, c) production of secondary cytokines with antileukemic activity, and d) the induction of programmed cell death (apoptosis) in leukemia cells. The results of these studies will demonstrate the value of combining this novel approach of site-directed TNFa gene therapy with other commonly used anticancer treatment strategies to achieve maximum destruction of residual leukemia. This would make possible the rapid implementation of this novel treatment strategy to eradicate residual leukemia in humans, without the toxic side effects of systemic TNF-a therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: DEPSIPEPTIDE: A NOVEL HISTONE DEACYTLASE INHIBITOR IN L Principal Investigator & Institution: Byrd, John C.; Internal Medicine; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2002; Project Start 07-JUN-2002; Project End 31-MAR-2004 Summary: (provided by applicant): A fine balance between the enzymatic activity of histone acetyltransferase and histone deacetylase (HDAC) governs levels of posttranslation acetylation of histone lysine residues. Recognition of this regulatory mechanism for gene transcriptional activation is growing. In cell transformation, acetylation is profoundly altered, and accumulation of hypoacetylated histone species occurs. Depsipeptide is a novel HDAC inhibitor completing phase I development in solid tumors; clinical activity has been noted. Studies by our group have shown selective cytotoxicity of depsipeptide toward acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) cells compared to normal hematopoetic cells. This cytotoxic effect occurs via an uncommonly exploited pathway of apoptosis, and the effect appears to be related to increasing histone H3 and H4 acetylation. We have
22 Leukemia
demonstrated the ability of depsipeptide to induce gene transcription, cell differentiation, and expression of adhesion/co-stimulatory molecules in human myeloid cell lines and transformed lymphocytes. Synergy with decitabine and up-regulation of the 1D10 antigen was also noted. Based upon these data, we propose to perform the first clinical trial of depsipeptide in leukemia patients in two separate cohorts (AML and CLL). The objectives of our proposal are to 1) determine the safety of administering depsipeptide to two cohorts of leukemia patients (AML and CLL) 2) determine the dose at which a 100 percent increase in the baseline histone acetylation occurs, which will define a minimal effective pharmacologic dose (MEPD) 3) examine the biologic effect of depsipeptide on leukemia cells treated in vivo in patients with CLL and AML with respect to differentiation (AML) and co-stimulatory/adhesion molecule expression(AML and CLL). The specific relationship of these processes to lysine-specific H4 alterations, inhibition of HDAC enzyme activity, and enhanced ex vivo sensitivity to monoclonal antibodies will be assessed. By utilizing this novel study design that target MEPD, we may achieve significant biological effects, while avoiding excess doses of depsipeptide. The clinical and laboratory results of this trial will provide pharmacokinetic and pharmacodynamic information for additional correlative efforts in both single agent phase II and combination phase I studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: EFFECT OF ANTIBODIES/CHEMOTHERAPY ON CHILDHOOD LEUKEMIA Principal Investigator & Institution: Herrera, Larry; Scott and White Memorial Hospital 2401 S 31St St Temple, Tx 76508 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Acute lymphoblastic leukemia (ALL) is the most common form of childhood malignancy. Chemotherapy can cure 80% of these children, but unfortunately many still relapse or develop resistant disease. Those that survive often suffer from adverse toxicity. This proposal investigates the mechanisms by which monoclonal antibodies (Mabs) induce apoptosis alone or in combination with chemotherapy in childhood B-lineage ALL. B-lineage lymphoblasts obtained from patients with leukemia undergo spontaneous and chemotherapy induced apoptosis. Like their normal counterparts (i.e., lymphocytes), they are "primed" to undergo apoptosis. Mabs have been shown to enhance the effect of chemotherapy in both laboratory and clinical settings. Mabs are capable of signaling various intracellular events and modulating the expression of genes involved in apoptosis. There exists only limited information on how Mabs and chemotherapy work together to enhance the cytotoxic effect upon leukemia. There is currently a lack of understanding of the mechanisms involved when Mabs are used to target B-lineage ALL as individual agents or in combination with chemotherapy. Our hypothesis is that the leukemia cell can undergo apoptosis in response to Mabs, the response can be enhanced with chemotherapy; and that key apoptotic related genes will be up-regulated or downregulated, thereby elucidating the pathway leading to cell death. Knowledge of this pathway may allow for the selection of agents capable of enhancing the degree of apoptosis. We plan to correlate the cellular response to a specific profile of mRNA expression. These studies may identify genes that are important in the initiation of apoptosis that have not previously been linked with this phenomenon. These studies will also allow us to determine if the degree of apoptosis demonstrated in vitro correlate with drug sensitivity in vivo. We will determine if apoptosis and gene profile analysis can predict the most effective agents in treating leukemia in a SCID/human ALL mouse
Studies
23
model. We will then develop new treatment regimens for children with multiply relapsed leukemia based on this information. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: FLT3 GENOTYPES IN ACUTE MYELOID LEUKEMIA Principal Investigator & Institution: Whitman, Susan P.; Comprehensive Cancer Center; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Acute leukemia is a malignancy of the hematopoietic elements that results at least in part from inappropriate activation of tyrosine kinases (TK). The most frequent somatic mutation associated with adult acute myeloid leukemia (AML) to date is the internal tandem duplication (ITD) of the FLT3 gene, a member of the Type III PDGF superfamily of receptor TKs. The FLT3 ITD defect results in the constitutive activation of the tyrosine kinase in the absence of ligand binding. Clinical studies thus far, however, have provided contradictory results with regards to presence of FLT3 ITD and prognostic significance of this defect in AML. These inconsistencies may be due to factors known to have confounding prognostic importance, such as varying cytogenetics, age, and treatment regimens. We examined a group of AML patients homogeneous for age, cytogenetics and treatment, and all considered at standard risk for relapse following therapy. We demonstrated three distinct genotypes among 82 patient samples examined: patients homozygous for the wild type (WT) FLT3 gene; patients heterozygous (FLT3ITD/WT), and patients hemizygous, i.e., FLT3 ITD in the absence of the WT gene, or FLT3ITD/-. Only the latter was a highly significant predictor of profoundly worse prognosis in AML patients compared to the others considered at standard risk. The overall research objective outlined in this proposal is to understand the mechanism by which the hemizygous genotype confers an especially poor prognosis, and to target this molecular defect in vitro and in vivo with a FLT3-specific inhibitor. To accomplish this goal, AIM 1 will investigate if a constitutively active mutant FLT3 in the absence of wild-type FLT3 confers a dominant positive gain-of-function role using in vitro and in vivo models. AIM 2 will assess whether proliferation and survival of FLT3 ITD-positive patient AML cells are selectively inhibited via induction of apoptosis by newly developed FLT3 inhibitor compounds. Funding of this K01 Mentored Minority Career Development Award will provide invaluable training for the applicant in the area of molecular mechanisms of disease, animal models for the study of human leukemia, and molecular targeted approaches to cancer therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: FUNCTIONAL ANALYSIS OF THE HUMAN LEUKEMIA GENE E2APBX1 Principal Investigator & Institution: Kamps, Mark P.; Pathology; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2002; Project Start 10-APR-1992; Project End 31-MAR-2007 Summary: (provided by applicant): PBX, MEIS/PREP, and HOX genes encode interacting transcription factors that regulate development. Their mutation produces oncogenes that cause human leukemia and other tumors. Pbx, Meis/Prep, and Hox proteins are also implicated as subordinate oncoproteins functionally required for leukemogenesis by other human oncogenes. Thus, understanding oncogenesis by individual Pbx, Meis/Prep or Hox oncogenes will yield a broader understanding of
24 Leukemia
human leukemia in general. This proposal focuses on understanding how Pbx proteins control development and hematopoiesis (Aims 1 and 2) and how the human E2a-Pbxl oncogene causes AML and preB ALL (Aims 3 and 4). Health-relatedness: Just as understanding oncogenesis by signal transduction oncoproteins led to the development of therapeutic inhibitors of cell proliferation, so also understanding the biochemical mechanism of oncoproteins that block hematopoietic differentiation will establish a rational to generate drugs that inhibit their function and promote differentiation. Because oncogenes that promote proliferation and inhibit differentiation cooperate to cause leukemia, drugs that inhibit proliferation and promote differentiation should cooperate to cure leukemia. Aim 1. Determine how Pbx homodimerization (in the absence of DNA) and Pbx:Meis/Prep heterodimerization regulate DNA-binding and nuclear import of Pbx proteins. Determine how Pbx proteins function as transcriptional coactivators. Aim 2. Using knockout technology, determine the role of Pbx2 in mouse development in general, and in regulating lineage commitment, differentiation progression, and gene transcription during hematopoiesis in particular. Make conditional Pbx2/Pbxl, or Pbx2/Pbx3 mice to determine the effect of double knockouts on hematopoietic differentiation. Aim 3: Use conditional E2a-ER-Pbxl to determine how E2 about-Pbxl prevents transcription of myeloid differentiation genes, focusing, mechanistically, on MRP8. Determine whether direct E2a-Pbxl targets reestablish a differentiation block in conditionally-immortalized E2a-ER-Pbxl myeloblasts and are activated in human t(l;19) pre-B ALL (L-Myc is one such target). Aim 4: Establish the cellular impact of E2a-Pbxl in models of pre-B cell leukemia induced by coexpression of Ras6l L plus E2a-Pbxl, or in transgenic mice expressing wild-type or conditional E2a-ERPbxl genes driven by the early, hematopoietic specific, Vav promoter. Identify the biochemical domains of E2a-Pbxl required to cause pre-B ALL, and begin to identify a genetic mechanism by which E2a-ER-Pbxl causes pre-B cell ALL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: GAT62 LEUKEMOGENESIS
IN
ONTOGENESIS,
HEMATOPOIESIS,
AND
Principal Investigator & Institution: Pandolfi, Pier P.; Professor; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 01-JUN-2000; Project End 31-MAY-2002 Summary: Chronic myelogenous leukemia is characterized by the presence of the chimeric p210 bcr/abl protein which shows elevated protein tyrosine kinase activity relative to the normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain constitutively tyrosine phosphorylated protein, GAT62 (GAP-associated with tyrosine phosphorylated p62), that migrates at 62 KD by SDS page and associates with p120 bcr/abl GTPase-activating protein (GAP). The gene encoding for this protein has very recently been identified. The focus of this proposal is to elucidate the role of the GAT62 protein in development and hemopoiesis, and to clarify how GAT62 function relates to leukemogenesis with the following Specific Aims: 1. To define in knock out mice and null ES cell lines, the role of GAT62 in ontogenesis and hemopoiesis. We will characterize GAT62 expression in the developing embryo and in the adult mouse. Using homologous recombination technology, we will disrupt the GAT62 gene in mouse Embryonic Stem (ES) cells and mice or embryos homozygous for the GAT62 inactivating mutation will be generated and studied. We will define the developmental role of the GAT62 gene by characterizing the embryonic or adult phenotype resulting from its inactivation. We will specifically study hemopoiesis in GAT62 mutants. Different experimental approaches will be undertaken
Studies
25
depending on whether mice lacking GAT62 re viable or on the stage of embryonic development at which they die. In parallel, we will produce GAT62 null ES cells and study the capacity of these cells to differentiate towards hemopoietic precursors in vitro and in vivo in chimeras and RAG-/- complementation assays. 2) To establish the role of GAT62 in leukemia promotion and progression. We will define whether the tyrosine phosphorylation and the resulting functional activation of GAT62 by the bcr/abl fusion products is a crucial event in CML and ALL (Acute Lymphoblastic Leukemia) leukemogenesis. To this end we will interbreed transgenic mice harboring the p210 bcr/abl and p190 bcr/abl fusion genes in the germ line, that develop leukemias through the activity of the chimeric proteins, with the GAT62 knockout mice in order to generate transgenes for the p210 bcr/abl and p120 bcr/abl fusion molecules in a GAT6 /- and -/genetic background. Hemopoiesis and leukemogenesis in the resulting transgene combinations will be analyzed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: LEUKEMIA
GENE
REARRANGEMENT
AND
EXPRESSION
IN
T-CELL
Principal Investigator & Institution: Goorha, Rakesh M.; Member; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2001; Project Start 01-FEB-1988; Project End 31-DEC-2002 Summary: Our long-term goal is to understand the molecular mechanisms operative in proliferation and differentiation of lymphocytes because perturbations in these processes results in leukemias. LMO-2 (Rhom-2/RBTN-2/ttg-2) locus at chromosome 11p13 is specifically disrupted in 10% patients with childhood T cell acute lymphoblastic leukemia (ALL). The oncogenic effects of LMO-2 are T cell specific; transgenic mice over-expressing LMO-2 in all tissues do not show any type of cancer other than T cell leukemias. It is hypothesized that LMO-2 mediates leukemogenesis by binding to other transcription factors and modulates their activity. Oncogenic specificity of LMO-2 may be because it binds a transcription factor with thymocyte specific expression. Accordingly, we have identified a novel transcription factor (Elf-2) that binds LMO-2 and its pattern of expression in normal and leukemic thymocytes strongly suggests that it plays an important role in leukemogenesis. We will conduct structure-function studies of Elf-2 to define its normal function and its role in leukemogenesis. Elf-2, in association with LMO-2, may alter the expression of genes that regulate thymocyte proliferation. Thus, a complementary approach to understand the mechanism of LMO-2 action is to identify its downstream target genes whose expression is altered in leukemic cells. Recently, using Representational Difference Analysis technique, we have isolated several clones that represent potential LMO-2 target genes. Cognate mRNA for one of the cones (a23) is not expressed in normal thymocytes but it is highly expressed in expanded double negative (DN) thymocytes and every mouse T cell (but not in B lineage) leukemias. Clone a23's invariant but ectopic expression in DN thymocytes and in every T cell leukemia strongly suggests that it play an important early role in leukemogenesis. We plan to characterize full-length cDNA representing clone a23 and conduct functional studies to determine its normal function and its role in leukemogenesis. After achieving remission, approximately 30% of the patients with T cell acute lymphocytic leukemia (ALL) relapse due to the resurgence of residual leukemic cells that can not be detected during remission of morphological methods. We have used a very sensitive PCR based assay to detect the residual leukemic cells and found that it has great potential in predicting impending relapse. We are now conducting a prospective study employing adequate number of patients to assess the
26 Leukemia
use of this technique in predicting relapse, monitoring the efficacy of anti-leukemic therapy, and long-term survival. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: GENETIC ANALYSIS OF A FAMILIAL LEUKEMIA SYNDROME Principal Investigator & Institution: Gilliland, D Gary.; Associate Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-MAR-2002 Summary: Despite remarkable advances in therapy of leukemia over the past 3 decades, the majority of adult patients with leukemia die from complications of their disease or therapy. There is convincing evidence that leukemia, like other cancers in humans, is the consequence of multiple mutations. Although significant strides have been made in identification of genes implicated in pathogenesis of leukemia over the past decade, little is known about the initiating events in the pathogenesis of leukemia. The deficit in our understanding of the early events in the molecular pathogenesis of leukemia is due in part to the rarity of familial predisposition to leukemia. In contrast with cancers such as breast and colon cancer, in which an inherited cancer predisposition has allowed for linkage analysis and positional cloning of the "first hit" mutations transmitted in the germline, there are few leukemia-prone families that would allow for an analogous approach. However, we have identified an extended pedigree characterized by a predisposition to develop leukemia. Furthermore, the trait is "marked" at birth by a platelet defect that has allowed for reliable identification of affected individuals. The goal of this proposal is to identify the gene that is responsible for this inherited leukemia syndrome, which in turn may provide critical information about the early genetic events in the pathogenesis of leukemia. Using a generalized linkage approach, we have localized the gene that causes the inherited predisposition to leukemia to a small region of human chromosome 21q22.1. In addition, we have recently identified a second pedigree with the same clinical phenotype which also demonstrates linkage to chromosome 21q22.1. Thus, there is convincing evidence to implicate this locus in pathogenesis of inherited leukemias. The goal of this proposal is to identify the gene which is responsible for the familial platelet disorder with propensity to develop AML. Our approach, as detailed in the body of the proposal, will focus on mutational analysis of genes which map to this region. Based on experience with other inherited cancers, we would predict that mutations in the FPD disease gene will also be relevant in sporadic leukemias, and will provide valuable information about the early genetic events in leukemia. In turn, this information may provide insight into novel therapeutic approaches to treatment of leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: GENETIC AND BIOCHEMICAL ANALYSES OF MLL CLEAVAGE Principal Investigator & Institution: Hsieh, James J.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The mixed-lineage leukemia gene (MLL, ALL1, HRX) encodes a 3,969 amino acid nuclear protein homologous to Drosophila trithorax and is required to maintain proper Hox gene expression. Deregulation of Hox and perhaps other gene expression causes transformation of segmental identities and contributes to human malignancy. Chromosome translocations in human leukemia disrupt MLL (11q23), generating chimeric proteins between the N-terminus of MLL and
Studies
27
multiple translocation partners. More than 20 MLL translocation partners have been identified. They vary widely from nuclear factors to cytoplasmic structural proteins and there are no common characteristics identified among them. However, mouse models demonstrated an indispensable role played by the various fusion partners in MLL leukemias. Gene expression profiles of human leukemia bearing an MLL translocation identified a pattern of upregulated genes. Among these genes were some of the wellrecognized targets of wild type MLL. This argues that the common MLL N-terminus is sufficient to confer at least some target gene specificity to MLL-fusion proteins. However, the mechanism by which MLL regulates downstream gene expression is still unclear. In preliminary studies, I demonstrate that MLL is normally cleaved at two conserved sites (D/GADD and D/GVDD) and that mutation of these sites abolishes the proteolysis. The cleavage site sequences are highly conserved from flies to mammals. MLL cleavage generates N-terminal p320 (N320) and C-terminal p180 (C180) fragments, which then interact to form a stable complex that localizes to a subnuclear compartment. Disruption of the interaction between N320 and C180 leads to a marked decrease in the level of N320 and a redistribution of C180 to a diffuse nuclear pattern. Based on these data, I propose a model in which a dynamic post-cleavage association confers stability to N320 and directs correct nuclear sublocalization of the complex, thereby controlling the availability of N320 for target gene regulation. This model predicts that MLL-fusion proteins of leukemia lose the ability to complex with C180 and instead have their stability conferred by the fusion partners, thus providing one mechanism for the altered target gene expression observed in MLL leukemic cells. Further characterization of MLL cleavage will help elucidate how MLL regulates target genes, which is crucial for both development and leukemogenesis. In this regard, I propose the following specific aims: (1) Characterize the MLL cleavage and determine its role in protein stability and nuclear sublocalization; (2) Generate knock-in mice with a noncleavable MLL; (3) Identify and characterize the protease responsible for MLL cleavage. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: GENETIC MANIPULATION OF T CELLS--PRECLINICAL MODELS Principal Investigator & Institution: Dipersio, John F.; Cheif, Division of Oncology; Medicine; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Applicant's Description Verbatim): Allogeneic bone marrow transplantation is a curative therapy for hematologic malignancies, marrow failure states, and selected inherited metabolic diseases. Unfortunately, BMT is associated with significant morbidity and mortality related to graft vs. host disease (GvHD). Attempts to mitigate GvHD using T-cell depletion resulted in increased rates of graft failure, post-transplant lymphoproliferative diseases, leukemia relapse and opportunistic infections. We propose to genetically modify T-cells using novel cell surface chimeric suicide genes. We will test the expression and purification of novel fusion suicide genes in vitro and in vivo using instructive transgenic and "knock-in" murine pre-clinical models. The optimal method and potential role of genetically manipulated T-cells to mitigate GvHD while maintaining engraftment and graft vs. leukemia can only be defined by developing new reagents and novel pre-clinical murine transplant models. We propose to generate important new reagents to study T-cell transduction by suicide genes and to use a number of well-defined pre-clinical models to develop a rational approach and a clear foundation for future clinical trials. In Aim I, we will design methods to optimize transduction, selection, and expansion of transduced T-cells, using OKT3 and 11-3 and CD3/CD28 magnetic beads. In addition, we will generate novel second-generation
28 Leukemia
suicide genes designed to optimize detection and killing in response to prodrug. We will also test the survival and function of transduced murine and human T cells using in vivo using allogeneic transplant models and several murine SCID models. Aims II and III, we will use the chimeric suicide genes developed in Aim I to generate informative transgenic and knock-in pre-clinical murine models in which these suicide genes will be expressed in all (Aim II) or in subsets (Aim III) of peripheral T-cells. Allogeneic bone marrow transplantation will be performed using the transgenic and knock-in mice developed in Aims II and III to further develop the optimal method of suicide in vivo, its effect on GvHD and engraftment, and its possible role in clinical trials. In Aim 1V, we will utilize three novel murine leukemia models in which the effects of genetically modified T-cells and their in vivo suicide on GvHD, engraftment and graft vs. leukemia can be compared to animals receiving unmanipulated T-cells and T-cell depleted BM. These studies will provide new insights into the pathophysiology of GvHD and its effective treatment. Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: GVL AGAINST MURINE CHRONIC PHASE AND BLAST CRISIS CML Principal Investigator & Institution: Shlomchik, Warren D.; Assistant Professor; Comprehensive Cancer Center; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2003; Project Start 05-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): The Graft-vs-Leukemia effect (GVL) mediated by T cells that accompany allogeneic stem cell grafts and delayed leukocyte infusions (DLI), has revolutionized the treatment of leukemia and lymphoma. Chronic phase CML (CPCML) is the prototypical GVL-sensitive neoplasm in which complete remissions are achieved in 80% of recipients of DLI. In spite of this success, alloimmune therapy has two principle weaknesses. First, many neoplasms including CML in blast crisis (BCCML), are GVL-resistant. The basis for this differential susceptibility is unknown. Second, GVL has proven difficult to separate from Graft-vs.-Host Disease (GVHD), the attack by donor T cells on recipient tissues. We hypothesize that manipulation of alloimmune responses can render GVL-resistant tumors more sensitive and lessen GVHD while retaining GVL. We believe this is possible because some patients with GVL-resistant disease do benefit from alIoSCT and some patients have GVL without GVHD. A first step in developing such strategies is to understand alloimmunity against GVL-sensitive neoplasms and how this response differs from GVHD and from GVL against less sensitive neoplasms. These are the objectives of this proposal. A major obstacle in achieving these goals has been the absence of murine models for GVLsensitive and resistant leukemias that share a common pathology and genetic etiology with their human counterparts and are inducible on different strains, including KO mice that will yield leukemias lacking critical molecules. Leukemia cell lines, the mainstay of murine GVL research, lack these features. We have adopted novel murine models of CPCML (mCP-CML) and BC-CML (mBC-CML) that address these problems, mCP-CML is a myeloproliferative disorder induced via retroviral transduction of murine progenitors with the bcr-abl fusion cDNA, the defining genetic abnormality in human CP-CML. mBC-CML is induced via the retroviral introduction of both bcr-abl and the NUP98/HOXA9 fusion, a translocation found in BC-CML. The use of retrovirus allows the induction of both leukemias in any mouse, most notably gene-deficient mice. Using
Studies
29
gene deficient recipients, donors, and leukemias, we will examine antigen presentation, T cell polarization, and T cell effector mechanisms in GVL and GVHD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: HOXA9 GENE AS A THERAPEUTIC TARGET IN LEUKEMIA Principal Investigator & Institution: Lawrence, Hugh J.; Professor of Medicine; Northern California Institute Res & Educ San Francisco, Ca 941211545 Timing: Fiscal Year 2001; Project Start 12-APR-2001; Project End 31-MAR-2003 Summary: (provided by applicant) A growing body of evidence supports the notion that misexpression of the HOXA9 homeobox gene is a common and critical event in myeloid leukemogenesis. Enforced expression of HOXA9 in murine marrow cells is clearly leukemogenic, and the gene is aberrantly upregulated in a large majority of cases of human acute myelogenous leukemia (AML). In a recent survey of 6,800 human genes in acute leukemia, HOXA9 expression was shown to be highly specific for AML and was the single best marker for a poor outcome. The major hypothesis of this grant is that aberrant activation of HOXA9 is a frequent downstream consequence of many, if not most, oncogenic events that lead to AML, and that this activation is critical to the induction and maintenance of the malignant phenotype. An additional key hypothesis is that HOXA9 overexpression contributes to the drug resistance phenotype. The focus of this application is to explore strategies to inhibit HOXA9 expression and/or function as a novel therapeutic approach for AML. This project has 3 major aims: i) to test the in vitra biologic effects of over-expression of HOXA9 in a factor-dependent nonleukemogenic myeloid cell line engineered to express high levels of HOXA9 in a tetracycline-regulatable manner, and to use this inducible cell line model to test strategies to block HOXA9 expression. ii) to develop an in vivo model of a Tetregulatable HOXA9-driven AML in mice, which can be used to test treatment the strategies developed in Aim #1 in a whole animal, and iii) to study the ability of antiHOXA9 strategies to alter the proliferation, differentiation and chemotherapeutic sensitivity of fresh leukemic cells from patients, and of human myeloid leukemic cell lines that show high levels of endogenous HOXA9 expression. The specific strategies to be tested include the use of conventional antisense oligonucleotides, double-stranded DNA decoys, and double-stranded RNA to induce RNA interference. We anticipate that therapies targeting the expression and/or function of HOX proteins could have a major role in the clinical treatment of leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: IMMUNOGLOBULIN GENE ARRANGEMENT/EXPRESSION IN LEUKEMIA Principal Investigator & Institution: Campana, Dario; Member; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2003; Project Start 01-JUL-1991; Project End 31-JAN-2006 Summary: (provided by applicant): By identifying patients at high risk of relapse, residual disease assessment promises to increase the cure rate of children with acute lymphoblastic leukemia (ALL). The quantity of residual, morphologically undetectable disease (minimal residual disease or MRD) present during therapy is an independent predictor of patient outcome. Although polymerase chain reaction assays can quantify MRD, simpler methods are needed for clinical application. In the previous funding period, simple automated fluorescence detection assays were developed for quantification of B- and T-cell antigen receptor gene rearrangements, which can be used
30 Leukemia
as leukemia-specific markers in 90 percent of ALL cases. The studies now proposed will determine the utility of these assays for quantification of leukemic cells in clinical samples (Aim 1). Universally applicable ALL markers are also needed for the integration of MRD assays into clinical protocols. Our previous studies showed that the neural gene, R-cadherin, is ectopically expressed in ALL but not in normal hematopoietic cells. Expression of R-cadherin should serve as a marker of recurrent leukemic cells and as an indicator of treatment-refractory ALL. The proposed studies will determine whether expression of R-cadherin can identify patients at a high risk of relapse and evaluate the efficacy of therapy (Aim 2). The application of ultra-sensitive MRD assays can be used to address an emerging problem in the treatment of ALL. Current intensive therapy has caused a delay in the timing of hematologic relapse. Assessment of MRD at end of therapy should permit identification of those patients with greatest risk of post-therapy relapse (Aim 3). The development of new automated MRD assays and the identification of new markers of leukemia should improve residual disease evaluation and thereby improve risk-directed therapy selection for every child with ALL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: LEUKEMIA THERAPY WITH MIHA SPECIFIC T CELLS Principal Investigator & Institution: Chen, Wei; Pediatrics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 06-AUG-1999; Project End 31-MAY-2003 Summary: Allogeneic bone marrow transplantation (BMT) has been successfully applied in the treatment of hematological malignancies. The eradication of leukemia following allogeneic BMT is in part due to due to a graft- versus-leukemia (GVL) effect mediated by the donor T cell. Clinically, the GVL effect is associated with a donor T cell-mediated graft-versus- host disease (GVHD), which is commonly fatal. In patients receiving BMT from HLA-matched donors, host antigens responsible for GVHD and GVL effect are functionally defined as the minor histocompatibility antigens (MiHA). The MiHA system is poorly characterized and few MiHA proteins responsible for GVL and/or GVH effects have been identified. Several studies indicated that MiHA may have selective tissue-restricted expression. The current grant will develop leukemia therapy with donor CD4+ and CD8+ T cell subsets specific for host hematopoietic tissuerestricted MiHA in murine models. The hypothesis to be tested is that targeting donor T-cell immunity against MiHA exclusively expressed on host hematopoietic cells may preserve a curative GVL effect without causing GVHD. The functional distinct MiHAspecific donor CD4+ and CD8+ T cell subsets may differentially mediate the processes in GVL effect and GVHD. The insights gained from this study may advance the understanding of the role of donor T cell subsets in mediating GVL and GVH effects and enable us to develop new therapeutic strategies for overcoming the clinical problem currently preventing the successful treatment of leukemia with donor T cells following allogeneic BMT. The specific aims are: 1. To analyze the therapeutic efficacy, toxicity and mechanisms of donor CD4+Th1 and Th2 subsets specific for host hematopoietic tissuerestricted MiHA. 2. To assess the therapeutic efficacy, toxicity and mechanisms of donor CD8+ Tc1 and Tc2 specific for host hematopoietic tissue-restricted MiHA. 3. To develop methods develops for in vitro induction of MiHA-specific T cells for leukemia therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
31
Project Title: MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB Principal Investigator & Institution: Truitt, Robert L.; Professor; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2001; Project Start 01-SEP-1984; Project End 31-JAN-2003 Summary: (Applicant's Abstract) Graft-vs-host disease (GVHD) is a potentially lethal complication of allogenic bone marrow transplantation (BMT). A reliable strategy to successfully treat GVHD once initiated has not yet been developed. The applicant has shown that F(ab')2 fragments of CD3 epsilon specific MoAb administered to mice after allogeneic BMT reverses the clinical effects of GVHD and leads to tolerance induction. In leukemia-bearing hosts, however, excessive or ill-timed administration of anti-CD3 F(ab')2 leads to leukemia relapse. The primary goal of this research is to identify mechanisms responsible for the successful treatment of GVHD with anti-CD3 F(ab')2 MoAb in vivo. Extensive preliminary data implicated cytokines in the pathology and regulation of GVHD. The two-part hypothesis to be tested states that (i) depletion of Tcells through activation-induced cell death (AICD or apoptosis) by anti-CD3 (Fab')2 MoAb is an essential prerequisite for treatment of established GVHD and (ii) anti CD3 F(ab')2 activates NK-1.1+ T-cells to secrete cytokines which lead to tolerance induction. Murine models have been developed to test this hypothesis. Four specific aims are proposed: (a) To assess the importance of AICD in the successful treatment of established GVHD with anti-CD3 F(ab')2 MoAb in vivo and correlate T-cell death with activation state of the T-cells in vitro and in vivo; (b) To determine whether NK-1.1+ Tcells or CD3+ double-negative T-cells contribute to suppression of GVHD after signaling through CD3 epsilon using phenotypic and functional assays in vitro; (c) To ascertain whether IL-4 or other cytokines are essential to the mechanism involved in therapy of GVHD with anti-CD3 F(ab')2 using homozygous deletion mutant mice ("knockout mice"); and (d) To examine immunological factors that contribute to post-BMT leukemia relapse after treatment with anti CD3 F(ab')2 MoAb and the ability of donor leukocyte infusions to prevent relapse. A unique aspect of the proposed studies is the parallel evaluation of the effects of MoAb therapy in vivo on graft-vs-leukemia (GVL) reactivity using acute T-cell lymphoblastic leukemia in AKR mice as a model. Mechanistic insights gained from the studies, together with the biological principles identified, will facilitate the translational application of MoAb to clinical BMT. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PROTEINS
MECHANISMS
OF
TRANSFORMATION
BY
MLL
FUSION
Principal Investigator & Institution: Martin, Mary E.; Pediatrics; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-JUL-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The goal of this five-year mentored clinical scientist development award is to secure for the applicant the intensive training and intellectual, scientific and educational environment requisite for development as a successful, independent physician-scientist. To this end, we propose an integrated program of research and study designed to elucidate the mechanisms of transformation by translocations of the mixed lineage leukemia gene (MLL, HRX, ALL-1) and to develop models of MLL-mediated leukemia. Despite intensive study and investigation, it remains unclear as to how MLL fusion proteins participate in leukemongenesis. MLL fusion proteins are the products of reciprocal translocation events where the MLL gene on chromosome 11q23 is combined with over 30 different translocation partners
32 Leukemia
resulting in lymphoid, myeloid and therapy-related leukemia's. Presumably the transforming effects of MLL fusion proteins are mediated through transcriptional deregulation, a gain of function activity contributed by the translocation partner. However, the remarkable number of translocation partners and the lack of homology among them have made it difficult to explain how they contribute to the oncogenic function of MLL. Emerging evidence suggests that transformation may be mediated through dimerization/oligomerization of truncated MLL. This model is attractive because it supplies a unifying hypothesis for the function of diverse MLL fusion proteins as well as exon duplicated forms of MLL that occur in some myeloid leukemias, and suggests a possible target for therapeutic intervention. The proposed research will aim to determine if dimerization or higher order oligomerization constitutes the mechanism of transformation by MLL fusion proteins. Additionally, we seek to establish a model of ALL using murine fetal liver retrovirally transduced with MLL-AF4, which is associated with infant ALL and for which appropriate animal models are lacking. Finally, we will establish a NOD/SCID model of MLL-mediated leukemia using human hematopoietic cells retrovirally transduced with bona fide MLL fusion proteins to further explore the mechanisms of transformation and to facilitate the future development of mechanism-based therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: MEMORIAL HOSPITAL AND CANCER AND ACUTE LEUKEMIA GROUP B Principal Investigator & Institution: Bosl, George J.; Chairman; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 30-JUL-1998; Project End 31-MAR-2003 Summary: (adapted from the applicant's abstract): This is the first application for support of Cancer and Leukemia Group B (CALGB) research activities by Memorial Sloan-Kettering Cancer Center (MSKCC) as a Main Member institution. MSKCC's mission is devoted to clinical and laboratory research related to cancer treatment and biology. Previously an affiliate of the New York Hospital, MSKCC became a Main Member in February 1996. This change from affiliate to Main Member represents our commitment to participate in a broad-based cooperative group in order to participate in national group and intergroup randomized trials and to interdigitate the national agenda into our extensive clinical trials program. Strong research interactions already exist between CALGB and MSKCC. Larry Norton, M.D., Chair, Breast Committee, and Jimmie Holland, M.D. first and only Chair, Psycho-Oncology Committee, both play dominant roles in shaping group and national clinical trials. In addition, Nancy Kemeny, M.D., is a member of the GI Committee and Medical Oncology Chair of CALGB 9481, studying intrahepatic chemotherapy in colorectal cancer patients with hepatic metastases. We plan to augment participation in these areas, and Clifford Hudis, M.D., and Andrew Seidman, M.D., are already actively presenting to the Breast Committee. Alice Kornblith, Ph.D., leads several psycho-oncology efforts, and Russell Porenoy, M.D., and Raymond Wesson, Ph.D., will join palliative care and minority issue efforts. Committee participation has expanded, with 19 MSKCC faculty appointed to 12 committees. Protocol accrual has increased, with 69 credits between 3/1/96 and 5/1/97, and 47 credits since 12/96 alone. Increased clinical trial accrual will result from newly activated CALGB therapeutic and nontherapeutic studies from additional disease and modality committees and, by introducing new drugs and biologics under development at MSKCC, into Group studies. This integration is under way. R.S.K. Chaganti, Ph.D., will participate in Leukemia/Lymphoma Correlative Sciences studies by providing the
Studies
33
introduction of comparative genomic hybridization into the study of malignant lymphomas. Accrual from affiliation with McGill University will augment MSKCC activities in CALGB. MSKCC looks forward to participation in CALGB's excellent group science. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: MOBILIZED BLOOD STEM CELL TRANSPLANTATION WITHOUT GVHD Principal Investigator & Institution: Strober, Samuel; Professor of Medicine; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 01-JAN-1997; Project End 31-DEC-2002 Summary: (Adapted from applicant's abstract) The goal of this application is to test the hypothesis that the T cells in bone marrow are qualitatively different than those in peripheral blood of normal mice and that after treatment with G-CSF, marrow T cells are mobilized into the blood. Preliminary data have suggested that marrow T cells have a markedly reduced capacity to induce lethal graft-versus-host disease after allogeneic marrow transplantation as compared to blood T cells but retain graft-versus-leukemia activity and an ability to facilitate engraftment. In order to test this hypothesis, the applicant will compare the surface markers, migration pathways, cytokine secretion patterns and capacity to induce lethal graft-versus-host disease, mediate graft-versusleukemia effects and facilitate engraftment by using highly purified T cell subsets from the bone marrow and blood of normal mice and from mice treated with G-CSF. Purified donor T cell subsets will be obtained by flow cytometry and injected together with T cell-depleted marrow in lethally irradiated MHC matched or mismatched recipients. Graft-versus-leukemia activity will be measured with the use of the BCL1 B cell leukemia, and graft facilitation will be measured using purified stem cells. Results of this study should help the design of clinical protocols of allogeneic marrow or mobilized blood cell transplantation in attempts to reduce the risks of graft-versus-host disease and recurrent malignancy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: MOLECULAR ANALYSIS OF TEL AND TEL/AML1 IN PREB LEUKEMIA Principal Investigator & Institution: Nucifora, Giuseppina; Associate Professor; Pathology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2001; Project Start 01-AUG-1997; Project End 31-JUL-2003 Summary: (adapted from the investigator's abstract) Recently, the fusion gene TEL/AML1 was cloned from children with B-lineage acute lymphoblastic leukemia (ALL). This disease is the most common childhood cancer, and it affects about 4 in 100,000 children in the United States. TEL/AML1 results from a chromosomal translocation between chromosomes 12 and 21, the t(12:21)(pl13;q22). Gene fusion occurs between TEL, located at chromosome 12 band p13, and AML1, located on chromosome 21 band q22. Although the t(12;21) is rarely seen by cytogenetic analysis, the TEL/AML1 fusion is detected in about 25-30% of childhood ALL by using molecular analysis. In addition, almost always the leukemic cells with TEL/AML1 have deletion of the normal TEL allele. Thus, the t(12;21) is unusual in that it requires two different mutations affecting the same gene: the inactivation of one allele of TEL, and the fusion of the second TEL allele to AML1. AML1 is a DNA-binding transactivator involved in several other different translocations associated with myeloid leukemias. TEL is a
34 Leukemia
member of the ETS family of transcription factors and contains a helix-loop-helix (HLH) motif at the N-terminal, necessary for protein dimerization. The working hypothesis is that TEL/AML1 is an altered transcription factor that inappropriately affects genes involved in B cell differentiation. In support of this hypothesis, results show that TEL/AML1 represses the activation by AML1. In addition, the investigators believe that, because the HLH motif is present in the normal TEL and in the TEL/AML1 fusion, the normal TEL might dimerize with TEL/AML1 and inactivate the inappropriate regulation by the chimeric gene. This would explain progressive deletion of the normal TEL allele. The long term objective of the proposal is to dissect the molecular mechanisms by which this chimeric protein affects the development of the hematopoietic cell and leads to leukemia. The major questions addressed in this proposal are: What proteins interact with TEL/AML1? Which genes does it regulate? and How does the leukemia progress? By using a combination of biochemical and molecular cloning techniques and tissue culture studies, the investigator will identify the proteins with which the chimeric genes interact and assess their role in cell transformation. Furthermore, they will use genetically altered animals which express the human fusion protein to evaluate the progress of the disease and to determine how hematopoietic genes are affected by the chimeric proteins. The experiments outlined in this proposal will allow them to begin to dissect the effects of TEL/AML1 in hematopoiesis and its contribution to leukogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: MOLECULAR DETECTION AND MONITORING OF LEUKEMIA Principal Investigator & Institution: Stock, Wendy; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: (provided by applicant): The major translational goals of molecular diagnostic and minimal residual disease (MRD) studies in the CALGB Leukemia Correlative Science Committee (LCSC) are to identify new prognostic groups and to utilize this information to adapt therapy to improve treatment outcome. We propose to consolidate all molecular diagnostic and MRD monitoring studies into a comprehensive "Molecular Detection and Monitoring Core" that will provide high quality data to Leukemia Committee clinical trials and to other LCSC projects and cores. The work will be performed in three disease-specific laboratories: Dr. Stock's laboratory (University of Chicago) for ALL and CML; Dr. Slack's (Roswell Park) laboratory for APL; and Dr. Gribben's (Dana Farber) laboratory for CLL. Several goals are proposed for Project 5. First, we will continue to utilize Real-time PCR technology for the prospective molecular detection of specific disease subsets and evaluation of MRD, correlating these findings with response to novel therapies as they are tested in the next generation of CALGB leukemia trials in ALL, APL, CML, and CLL. We propose that assessment of response using quantitative MRD monitoring as a surrogate endpoint provides unique clinical insights that will be particularly relevant as we perform the first generation of molecularly targeted CALGB leukemia trials described below in detail. A second goal of Project 5 is to validate the use of quantitative MRD monitoring as an independent prognostic marker of outcome for patients with acute and chronic leukemia. Prospective MRD evaluation of large, uniformly treated patient cohorts is essential for identification and validation of a "threshold" level of MRD that may distinguish patients at high (or low) risk of relapse. We also propose, for the first time in CALGB Leukemia studies, to utilize MRD monitoring to adapt and individualize post-remission therapy. A fourth goal of this Project is closely linked to Project 3, Gene Profiling Studies in
Studies
35
Leukemia. As new molecular "signatures" characterizing novel disease subsets are identified by gene profiling studies in Project 3, we will evaluate expression levels of new "molecular signature" genes in ALL, AML and CLL, using Real-time reverse transcriptase (RT)-PCR methodology. The correlation of gene expression using Realtime RT-PCR with microarray findings will be useful for validating these data and will provide important new diagnostic and prognostic information about new molecular genetic subsets that may be used to adapt therapy in future CALGB treatment trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: MOLECULAR MECHANISMS OF LEUKEMOGENESIS BY PMLRAR ALPHA Principal Investigator & Institution: Kogan, Scott C.; Assistant Professor; George Williams Hooper Foundation; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Acute promyelocytic leukemia (APL) is a form of acute myeloid leukemia (AML) associated with fusion of the retinoic acid receptor alpha gene with the gene encoding the PML nuclear protein. In APL, the leukemic cells are blocked at the promyelocyte stage of differentiation but can be induced to develop into mature neutrophils by treatment with retinoic acid. The use of retinoic acid to treat APL is a successful example of molecularly-targeted cancer therapy. The broad long-term objectives of the proposed work are to identify the combinations of genetic changes that result in AML and to delineate the mechanisms by which these changes transform normal blood cells into leukemias. The ultimate goal is to utilize this knowledge to improve treatment for human patients with leukemias and other malignancies. The specific research proposed in this application utilizes murine models of leukemia to (i) identify activities of the fusion protein PMLRARalpha that contribute to leukemogenesis and (ii) identify the molecular events that cooperate with PMLRARalpha in leukemogenesis. Activities of PMLRARalpha that may contribute to leukemia are abrogation of the normal function of PML and disruption of normal transcription in myeloid cells (including transcriptional repression of retinoic acid responsive target genes as well as inhibition of other transcription factors). The contribution of activities of PMLRARalpha to leukemogenesis will be assessed by expressing altered forms of PMLRARalpha in mice mutant versions of PMLRARalpha differentially impaired for specific functions will be tested for their ability to initiate leukemia. The development of novel retroviral-based models of APL to complement work with transgenic mice should facilitate assessment of the leukemogenic potential of these altered forms of PMLRARalpha. Additional changes that cooperate with PMLRARalpha are required for leukemogenesis in transgenic mice. Although the nature of these cooperating events is not clear, activation of growth factor receptors may contribute to leukemia. This hypothesis will be assessed by transducing PMLRARalpha-expressing bone marrow cells with retroviral vectors that drive expression of activated forms of IL-3 receptor or activated FLT3. Further, various mutant forms of activated receptors will be compared in regard to their ability to cooperate with PMLRARalpha. Correlating the ability of these mutants to cause leukemia with their different effects on growth factor signaling pathways should identify downstream events that have a central role in transformation. In addition, by examining whether the expression or activity of candidate mediators is abnormal in leukemic cells, molecules that participate in the pre-leukemia to leukemia transition will be delineated. The proposed studies should identify molecular pathways
36 Leukemia
and particular molecules that are central to the pathogenesis of AML. This work will aid the development of new molecularly-targeted treatments for these malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: MOLECULAR PROFILING IN LEUKEMIA Principal Investigator & Institution: Staudt, Louis; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: (provided by applicant): Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) each appear to be heterogeneous at the molecular level (Bloomfield and Caligiuri, 2000). During the past two decades, there has been considerable progress in identifying cytogenetic and molecular markers that can predict outcome following standard treatment for a fraction of patients with AML, ALL, or CLL. However, there still remains a sizable fraction of cases for which molecular predictors of prognosis are not clinically useful, because the malignant clone either lacks such an abnormality or because the abnormality is too infrequent to correlate with clinical outcome. The CALGB is a leader in using cytogenetic and molecular markers to stratify patients based on the risk of failure with standard treatment, and the identification of such indicators has become central to assignment of the appropriate therapy. This trend is likely to become even more critical in the future as more and more targeted therapies that are only active in molecularly defined subsets of patients become available in the clinic. Thus, a very high priority for the CALGB is to develop better and more robust molecular means to predict outcome in the hematologic malignancies. We will do this in conjunction with the Leukemia Committee, as described in that proposal. We hypothesize that genetic expression profiling using microarrays of diagnostic AML, ALL, and CLL samples that lack cytogenetic or molecular markers predictive of clinical outcome can identify a genetic expression profile or "signature pattern" that can be used to predict clinical outcome following standard therapy. A corollary to this hypothesis is that such a molecular profile could then be used for risk stratification of treatment and ultimately to improve clinical outcome in patients with AML, ALL, and CLL. Also, we hypothesize that Restriction Landmark Genomic Scanning (RLGS) can be used to identify prognostically significant DNA methylation patterns in CLL, with the same implications for clinical outcome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: MOLECULAR TAXONOMY OF PEDIATRIC AND ADULT ACUTE LEUKEMIA Principal Investigator & Institution: Willman, Cheryl L.; Professor; Pathology; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JAN-2005 Summary: Although remarkable advances have been made in the treatment of the acute leukemias, particularly resistant forms of leukemia remain. In 1999, 28,000 children and adults in the U.S. will be diagnosed with leukemia and 21,000 will die of their disease. This variability in clinical response is due in part to the tremendous heterogeneity of the disease itself. Traditionally classified solely on the basis of morphology and cytochemistry, the acute lymphoid or lymphoblastic leukemias (ALL) and the acute myeloid leukemias (AML) are characterized by highly variable clinical and biologic behavior, immunophenotypes, and chromosomal abnormalities. Striking differences in
Studies
37
outcome may be seen in cases with the same cytogenetic profile, implying that more subtle genetic abnormalities also impact disease biology and response. We hypothesize that cDNA microarray technology will yield quantitative, orderly, and systematic gene expression profiles that can be used to design more clinically relevant classification schemes and to predict therapeutic response. By conducting correlative science studies accompanying NCI-sponsored clinical trials in children and adults affected by acute leukemia for the Pediatric Oncology Group, Children's Cancer Study Group, and Southwest Oncology Group, and by maintaining the largest leukemia tissue repositories in the world, we are poised to propose the following specific aims: 1. To Further Optimize cDNA Microarray Technology for Studies in Primary Human Leukemia Samples. 2. To Characterize the Molecular Variations Among Highly Selected Acute Leukemia Cases Using at Least 30,000 Genes. Cases have been selected using two approaches: 1) therapeutic response/resistance and 2) the presence of specific cytogenetic abnormalities. Study sets in AML include: 1) patients with "primary resistant" disease; 2) patients in long-term remission; 3) paired pre-treatment and relapse samples; 4) patients responding or failing specific treatment regimens; and 4) cases selected by genotype [t(8.21), inv(16), t(15;17), t(4;11), t(9;11), and complex]. In ALL, cases are being selected prospectively using two approaches: 1) the presence of residual disease vs. complete molecular response during the treatment course using automated quantitative molecular monitoring methods; and 2) by genotype [hyperdiploid, t(12;21), t(9;22), t(1;19), and t(4;11)]. 3. To Apply Multivariate Clustering Methods to Group Acute Leukemias That are Coherent in their Expression Patterns. 4. To Use Automated Quantitative "Real-Time" PCR Technologies to Validate cDNA Microarray Analyses. 5. To Use High Performance Computing and Informatics Technologies to Link Large Genomic Data Sets with Clinical Databases. All leukemia samples have associated clinical databases containing detailed patient information, laboratory data (cytogenetics, correlative scientific studies), and therapeutic response data. Our experienced clinical trials biostatisticians will work with the UNM High Performance Computing Center (a National Supercomputing Facility) and Sandia National Laboratory (both world leaders in massively scalable parallel computing, statistics, informatics, and visualization tools) to meet this aim. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: NOVEL FUSION PROTEIN IN CMML Principal Investigator & Institution: Ross, Theodora S.; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 10-FEB-1998; Project End 31-JAN-2003 Summary: (Applicant's Description): The TEL-PDGFBR fusion protein was identified as the protein product of a t(5;12) translocation in a patient with chronic myelomonocytic leukemia (CMML). The protein fuses the amino portion of TEL with the transmembrane and cytoplasmic domains of the PDGFBR. TEL, a member of the ETS family of transcription factors, has subsequently been described as a common site of rearrangement in multiple forms of leukemia. This is not yet the case for the PDGFBR. The applicants find, however, in the Preliminary Results, that another patient with CMML has a novel t(5;7) translocation. Southern blotting analysis has identified a breakpoint in this patient at the same genomic localization in the PDGFBR as the t(5;12) translocation. Their hypothesis is, that in this patient, as for the t(5;12) TEL-PDGFR patients, PDGFBR is constitutively activated by fusion with a 7q24 partner. Although rare (as for identification of TEL), the PDGFBR fusion partner at 7q24 may identify a gene involved in a broader group of malignancies. Also, in light of the facts that other
38 Leukemia
patients with CMML have PDGFR containing fusions and the region of 7q24 is frequently deleted in MDS, the cloning, characterization and manipulation of this fusion protein is paramount. Hence, in Specific Aim 1, they will use anchored PCR to clone the breakpoint. Their specific oligos will come from the known PDGFBR sequence. In Specific Aim 2, they will obtain a full length cDNA and determine the relevance of this by performing ribonuclease protection assays and mapping back to chromosome 7. Finally, for Specific Aim 3 they propose to characterize the fusion protein by determining its transforming, activity(s) and biological properties using mutational and biochemical analyses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: ONCOGENES INVOLVED IN ACUTE MYELOID LEUKEMIA DEVELOPMENT Principal Investigator & Institution: Reuther, Gary W.; Comprehensive Cancer Center; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 03-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): The goal of this proposal is to identify and characterize novel oncogenes expressed in patients with acute myeloid leukemia (AML). The design of this proposal is to position the candidate for an independent career in basic cancer research, with a focus on leukemia, in an academic environment. Working in Dr. Channing Der's laboratory at the University of North Carolina at Chapel Hill has provided an excellent foundation for this career. With a little more guidance from Dr. Der, the candidate will utilize the outstanding resources that Dr. Der's laboratory and the University of North Carolina at Chapel Hill provide, in order to solidify the scientific basis for an independent career in research. The first two specific aims of this research proposal focus on characterizing a novel activator of Ras, RasGRP4, identified by the candidate in a screen for novel oncogenes in AML. RasGRP4 is primarily expressed in myeloid cells suggesting it has a specific role in these cells. Targeted disruption of the gene for RasGRP4 in mice will be utilized to characterize the normal function of RasGRP4. The development of the hematopoietic system of these mice will be analyzed along with signal transduction pathways that may utilize RasGRP4. These studies represent an excellent opportunity to expand the candidate's technical repertoire (e.g., animal model development and analyses of primary hematopoietic cells), by combining the resources provided by the UNC Chapel Hill animal model facility and Dr. Der's expertise on Ras signal transduction. The last aim of this proposal, which will be initiated in the independent phase of the award, is to perform additional screens for oncogenes in AML. AML formation requires two classes of mutations: one that induces cell proliferation and survival, and one that inhibits differentiation. AML1-Eto and CBFb-MYH11, two common oncogenes in AML, are not sufficient to induce leukemia. This proposal describes experiments to identify required mutations, expressed in AML patients whose leukemic cells harbor these fusion proteins, that cooperate with these oncogenes and also to identify members of both classes of AML oncogenes. This will provide an opportunity to expand and improve strategies aimed at identifying novel oncogenes in AML. In summary, this proposal provides an excellent opportunity for the candidate to complete his training to become an independent researcher. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
39
Project Title: ONCOGENESIS AND MYELOID TRANSCRIPTION IN AML Principal Investigator & Institution: Tenen, Daniel G.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-MAR-2007 Summary: (provided by applicant): Knowledge of the mechanisms underlying the normal development of blood cells is important in understanding and developing new treatments for various blood diseases, including leukemias. The long range goals of this project are to further our understanding of the mechanisms involved in leukemia by understanding the effects of various leukemia oncogenes on the transcription factors which regulate normal myeloid development from stem cells. Previous work in our laboratory has led to the identification of the transcription factor CCAAT Enhancer Binding Protein a (C/EBPa) as being absolutely critical for differentiation of normal myeloid blasts, and identified abnormalities in C/EBPa as playing a critical role in a number of specific types of Acute Myeloid Leukemia (AML), as noted in the Progress Report. Over the next 5 years, we propose to extend the study of how oncogenes affect this critical transcription factor in cell differentiation. We therefore propose the following Specific Aims: (1) To test the hypothesis that the interaction between PML/RAR and C/EBPa is responsible for the differentiation block in Acute Promyelocytic Leukemia (APL); (2) To understand the role of C/EBPb in the pathogenesis of APL? (Years 1-5); and (3) To investigate the synergism between loss of function of C/EBPa and leukemia oncogenes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kung, Faith H.; Associate Professor; Pediatrics; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators
40 Leukemia
will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Breitfeld, Philip P.; Pediatrics; Duke University Durham, Nc 27706 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The goal of the proposed research is to determine optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators in a consortium of medical institutions in North Carolina and West Virginia in collaborative multidisciplinary clinical cancer research protocols generated through the Pediatric Oncology Group. The proposed research grant will allow for the continued participation of Duke University Medical Center, Charlotte Memorial Hospital, East Carolina University School of Medicine and West Virginia University School of Medicine in Pediatric Oncology Group activities. These activities involve studies of the epidemiology and tumor biology of selected neoplasms and the natural history and optimum multimodal therapy of all childhood malignancies. Cooperative studies among physicians from a group of medical centers allow for rapid accrual of a statistically significant number of children with cancer in order to define quickly both those avenues of biologic research which have immediate clinical relevance and those therapeutic approaches which provide prolonged disease-free survival. Through participation in cooperative studies, the entire medical community engaged in the care of children with cancer has a focal point to provide not only improved patient care but also improved multidisciplinary teaching and research. Our objectives for the coming years are: 1) to develop new protocols for the immunologic stratification and chemotherapeutic management of patients with malignant lymphoproliferative and myeloproliferative disorders; 2) to develop protocols for specific brain tumor therapy which take advantage of our expanding knowledge of the biology and pharmacologic sensitivity of human brain tumors in vitro and in vivo; 3) to expand our studies of the pharmacologic agents which influence intermediary metabolism, using our in vitro data as the basis for drug scheduling in clinical trials; 4) to expand our innovative groupwide epidemiology studies to include studies of neuroblastoma and T-cell malignancies which include laboratory investigation (immunologic, biochemical and cytogenetic) where relevant; 5) to expand our multidisciplinary therapeutic research efforts in other pediatric malignancies; and 6) to expand our outreach programs for patient care and education through our regional consortium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Lauer, Stephen J.; Professor of Pediatrics; Pediatrics; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: The Pediatric Oncology Program at Emory University is the only comprehensive children's cancer center in Georgia and one of the largest of its kind in the Southeast. It serves a racially, ethnically, and socioeconomically diverse population from metropolitan Atlanta, the State of Georgia, and other states including Alabama,
Studies
41
Arkansas, the Carolinas, Florida, and Mississippi. Since the inception of the Pediatric Oncology Group (POG), Emory is consistently one of the largest single-institution contributors to POG clinical and laboratory studies. Emory is a center for Phase I and pilot POG trials and has initiated numerous protocols that have subsequently been implemented by POG. The specific aims of the Emory POG Program are: l) to continue as a major source of patients for POG-sponsored Phase I, pilot, groupwide, and intergroup studies; 2) to provide leadership by its investigators as POG Study Coordinators, Co- coordinators, and Core Committee members; 3) to develop innovative institutional clinical trials on which to base future POG investigations; and 4) to maintain strong basic and translational research programs in pediatric oncology. To address these aims, Emory investigators are Coordinators for several major POG studies, including standard-risk new ALL (#9405), high-risk new ALL (#9006), salvage chemotherapy in relapsed neuroblastoma (#9140), and chemotherapy vs. autologous bone marrow transplantation (ABMT) in AML (#8821). Emory POG members actively participate in POG Core Committees, Subcommittees, and new protocol development. Institutional pilot studies include therapy of relapsed AML with idarubicin and chlordeoxyadenosine, treatment of relapsed solid tumors with high-dose busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-escalated cyclophosphamide and infusions of peripheral blood-derived progenitor cells in refractory solid tumors. Complementary laboratory research activities include molecular biology of ALL (mechanisms of IL-6- mediated autocrine growth and aberrations in tumor-suppressor genes); in vitro sensitivity of leukemia cells to antineoplastic agents mid biological response modifiers; mechanisms of resistance of AML cells to alkylating agents; molecular neuro-oncology; and xenogeneic models to evaluate normal and neoplastic human hematopoiesis. Investigators at Emory are participating in the POG laboratory study of methotrexate metabolism by ALL cells (ALinC #16) and coordinate the study of alterations in p53 tumor-suppressor gene pathways in relapsed ALL (SIMAL #l0). Taken together, these activities of the Emory POG Program will continue to contribute to our knowledge of the biology, therapy, and prevention of neoplastic diseases in infancy, childhood and adolescence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Ravindranath, Yaddanapudi; Pediatrics; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2001; Project Start 01-JUN-1981; Project End 31-DEC-2002 Summary: This proposal is a request for funding for our continued involvement in the Pediatric Oncology Group (POG). The aims and objectives are to find better means of management for malignant diseases in children and adolescents, and thus increase disease-free survival rates. The Children's Hospital of Michigan (CHM) provides diagnostic evaluation and multimodal therapy for children throughout the State of Michigan. While there is one other Pediatric Oncology facility in the State, the Hematology/Oncology service sees almost all children and adolescents with malignant disease who live in the greater metropolitan Detroit area, and also sees large numbers of such children referred from other parts of the State (and from Canada) regardless of their ability to pay. Until 1979, the oncology service at CHM remained "independent". In September 1979, the CHM oncology team joined the pediatric division of the Southwest Oncology Group and in January 1981 joined the Pediatric Oncology Group, which appears to have even a greater potential for development of better treatment regimens
42 Leukemia
for childhood malignant disease. At the time of referral and/or admission to CHM for possible malignancy, each child is seen and evaluated by the appropriate oncology team members. Following appropriate diagnostic evaluation, each child is presented and discussed at the Tumor Board, which meets weekly and is attended by pediatric oncologists, pathologists, radiologists, surgeons, surgical subspecialities, and radiotherapists. A plan of action is outlined for each child's management. All such children are registered with POG, and whenever judged appropriate, children are entered on POG treatment protocols. By our participation in such a cooperative children's cancer group, our investigators are able to share new information and ideas and gain access to new multimodal therapy regimens and investigational drugs which hopefully provide the best available care to these children. Our objectives in the coming years are: 1) increased participation in POG cancer biology and epidemiology studies; 2) to continue our leukemia biology studies particularly pharmacology studies in AML/T ALL, and 3) to develop new strategies for treatment of brain tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Castleberry, Robert P.; Professor of Pediatrics; Pediatrics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 01-MAR-1979; Project End 31-DEC-2002 Summary: The University of Alabama at Birmingham (UAB) is a leading contributor to the ongoing clinical and basic research activities of the Pediatric Oncology Group (POG) which are focused upon improving the care and cure for children with cancer. Current results of these trials are in some cases already published and are available in the Progress Report. The leadership from UAB in POG is evident in several areas: l) through enrollment of substantial numbers of assessable patients on Phase I, II and III therapeutic trials, including multidiscipline (surgery, chemotherapy, and radiotherapy) management studies; through participation in and development of Group-wide biological studies of selected hematopoietic and solid malignancies; through evolving, coordinating and reporting data from POG therapeutic trials; and by providing discipline and disease committee, and administrative leadership within the group. UAB will continue to enroll all eligible patients on active POG therapeutic and biological studies, including phase I investigations, and maintain high evaluability. UAB investigators will continue to coordinate clinical trials for children with neuroblastoma, bone tumors, and juvenile chronic myelogenous leukemia (JCML) and to assess the therapeutic utility of IL6. Further, UAB investigators will be principal to the development of new studies in neuroblastoma, brain tumors, JCML and acute myelogenous leukemia. UAB will continue to supervise laboratories for POG in the following areas: 1) Banded chromosomal analysis in newly diagnosed patients with lymphoid leukemia; 2) A required reference laboratory for children with JCML (POG #9265) studying the pathogenesis of myeloproliferation; 3) A required serum/plasma repository (POG #9047) with clinical and demographic data referenced on a computer data base; and 4) A non- mandatory reference laboratory to evaluate the biological and clinical significance of rnicrotubular associated protein (MAP) and tubulin isotype expression in neuroblastoma. UAB investigators will continue their scientific and administrative leadership roles on the Neuroblastoma and Other Embryonal Tumors, Myeloid Disease Core, Biologic Response Modifier Core, Executive, Principal Investigator Core, Clinical Research Associate Core, and Diagnostic Imaging Core Committees. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
43
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kavan, Petr; Montreal Children's Hospital 2300 Tupper St Montreal, Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The Pediatric Oncology Group (POG) is a multi-disciplinary, multiinstitutional research community which collaborates to increase knowledge of and improve treatment for cancer and leukemia in children and adolescents. The Montreal Children's Hospital/McGill University (MCH), a founding member, requests funding for itself and its two affiliates, the Children's Hospital of Eastern Ontario (CHEO) and the University of Sherbrooke Medical Center (USMC) to continue to participate fully in administrative and scientific activities of the POG during the next 5 years. We expect to enroll a total of 70 patients a year on therapeutic protocols for childhood leukemias, lymphomas, solid tumors and brain tumors, with continued emphasis on Phase I and II studies of new agents and coordination or co-coordination of a minimum of 13 protocols. We expect to enroll 110 patients per year on non-therapeutic studies of cancer etiology, epidemiology, biology, psychologic impact and late effects of therapy with particular emphasis on the pharmacology and molecular pharmacology of methotrexate in acute lymphoblastic leukemia (ALL). We will comply with all requirements of the POG constitution, with MR regulations governing ethical conduct of clinical research and with OPRR and IRB requirements for informed consent and protection of subjects from research risks. In addition to an anticipated doubling of patient accruals since 5 years ago, our major contributions to POG research will include: confirmation that the extent of accumulation of methotrexate polyglutamates by lymphoblasts in B-progenitor cell ALL correlates with event-free survival (EFS) and characterization of the mechanisms regulating this metabolism (Whitehead); promotion of new agent drug development through New Agents and Pharmacology Committee leadership (Whitehead and Bernstein) and protocol coordination (Bernstein, Baruchel); introduction of stereotactic and fractionated stereotactic radiation therapy in brain tumors (Freeman); coordination of treatment protocols of newly-diagnosed and relapsed B-progenitor cell ALL (Abish, Bernstein); introduction of new agents and combinations in recurrent lymphoid disease as Sub-committee Chair, Lymphoid Relapse (Bernstein); chemotherapy and surgery of brain tumors (Baruchel, Ventureyra); and study of the biology, including p53 gene mutations, and treatment of HIV-related lymphomas (Baruchel, Whitehead). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Link, Michael P.; Professor; Pediatrics; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The overall goal of this research proposal is for Stanford University, the University of Arizona, and the Kaiser Permanente Medical Centers of the South San Francisco Bay Area to continue their active involvement in Pediatric Oncology Group research activities. Stanford faculty and the University of Arizona faculty have already assumed key leadership positions in POG and have or have had major roles in the scientific and administrative aspects of the Group. Further, Stanford, the University of Arizona, and Kaiser have maintained excellent performance ratings in their participation in POG studies and have received commendations for the large numbers of evaluable patients placed on therapeutic protocols. Specifically: l) We plan to
44 Leukemia
continue to enter patients on appropriate POG studies where they exist. The number of patient entries from Stanford has increased each year as appropriate POG studies become available. We anticipate that between 65 and 80 patients will be entered on front-line therapeutic studies each year from Stanford in addition to patients who will be entered from the affiliates; in addition, 40-50 patients or more will be entered on POG non-therapeutic studies. 2) We anticipate that the activities of individual investigators from Stanford and the University of Arizona will continue and increase during the period of this research proposal. Currently, our faculty serve as study coordinators for front- line therapeutic studies in lymphoma and leukemia, and they have coordinated and analyzed data from recently closed protocols in osteosarcoma, lymphoma, leukemia, and Ewing's sarcoma. Our faculty also serve key scientific and administrative roles as Group Vice Chair, Disease and Discipline Committee Chairmen and CoChairmen, as members of Disease and Discipline Core Committees, and as members of the Executive Committee. Thus, our faculty are in position to influence the future direction of the scientific activities of POG. 3) We anticipate that involvement of Stanford faculty in the laboratory scientific activities of POG will continue. The laboratories of Drs. Link and Cleary have served as immunology reference laboratories and molecular biologic reference laboratories for leukemia studies of POG. 4) We anticipate that non-POG related laboratory and clinical research conducted at Stanford University and its affiliates will become increasingly relevant to POG activities. Some of these activities have already been incorporated into POG laboratory and therapeutic studies and others are targeted for incorporation into future POG studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PEDIATRIC ONCOLOGY GROUP ACTIVITIES Principal Investigator & Institution: Buchanan, George R.; Pediatrics; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: This grant application seeks continued support for the Pediatric Oncology Group (POG) activities of The University of Texas Southwestern Medical Center (UT Southwestern) Consortium, which consists of UT Southwestern (Dallas), Cook-Ft. Worth Children's Medical Center (Ft. Worth), and Scott & White Clinic (Temple). Since joining POG in 1981, this partnership of children's cancer treatment and research centers in North Texas has grown to become POG's largest contributing member with regard to patients enrolled on therapeutic studies (over 100 annually). During the current grant cycle, consortium investigators have held administrative and scientific leadership positions on major Group committees, including Executive Committee, Principal Investigator's Committee, New ALL Committee, T-cell Committee, and Lymphoid Relapse Committee. UT Southwestern Consortium investigators have also served or are serving as study coordinators on multiple POG treatment protocols studying ALL (newly diagnosed patients with B-lineage and T-cell disease as well as following relapse), non-Hodgkin's lymphoma, bone marrow transplantation and new agents being explored in Phase I-II trials. UT Southwestern Consortium investigators have also had prominent roles in the arenas of data management, protocol development, molecular and pharmacologic monitoring in authorized POG reference laboratories, and supportive care. Results of pilot projects conducted at UT Southwestern have been instrumental in the construct of group-wide treatment strategies, especially involving use of methotrexate for B-lineage ALL. To support the UT Southwestern Consortium's continued commitment to POG research during the next 5 years, this new grant proposal describes personnel and facilities in the 3 consortium centers. Specifically,
Studies
45
during 1996-2000 the Consortium aims to advance POG research by: (l) enrolling as many patients as possible on POG treatment, biological classification, and epidemiology protocols; (2) collecting, recording, and submitting research data in an accurate and timely fashion; (3) providing administrative and scientific expertise to the Group through continued active participation on major committees, including service as disease committee chairs and protocol coordinators; and (4) continuing to conduct innovative in-house pilot studies for subsequent use by the Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PEDIATRIC ONCOLOGY GROUP PARTICIPATION Principal Investigator & Institution: Pui, Ching-Hon; Acting Chairman; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2001; Project Start 01-JAN-1982; Project End 31-DEC-2002 Summary: We propose continued participation in the Pediatric Oncology Group (POG). Our goals are as follows: (1) to improve cure rates for children with cancer through participation in Phase I, II, and III clinical trials designed to test new agents or concepts; and (2) to participate in laboratory-based research aimed at clarifying the basis of drug resistance and pathogenetic mechanisms of childhood cancers. We are committed to Group participation because we believe: (1) that collaborative efforts are both desirable and necessary for study of childhood cancers, since all are relatively rare; and (2) that well-designed randomized clinical trials provide the most definitive test of efficacy and general applicability of new therapies and that pooled intellectual resources are advantageous as well. Our contribution to the Group can be categorized as follows: (1) contribution of selected patients (those with rare tumors or less common stages of other cancers, n approximately 80-100/year) to Group studies; (2) administrative and scientific leadership (e.g., disease or discipline committee chairs, and protocol coordinators); (3) provision of multiple reference laboratories (flow cytometry analyses of leukemia and solid tumors, cell bank, AML cytogenetics, pharmacokinetics/pharmacodynamics, molecular genetics of leukemia and solid tumor); (4) regular presentation of results of in-house research to the group. Since our center has an unusually large number of patients and staff (both clinical and basic), the latter contribution assumes unusual importance. We have an extensive in-house developmental therapeutics program which is independent of, but complementary to, the Group's clinical research programs. We also have extensive programs in basic research. The aim of these programs, to determine the pathogenesis of pediatric neoplasia, is expected to positively influence the Group's central goal -- curing children with cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PEDIATRIC ONCOLOGY GROUP STUDIES Principal Investigator & Institution: Chauvenet, Allen R.; Pediatrics; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-DEC-2002 Summary: The overall objective of the proposed research effort is to continue work towards determining the optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators at the Bowman Gray School of Medicine in the development and execution of collaborative multidisciplinary clinical protocols of the pediatric Oncology Group. The proposed research grant will support the continued participation of the Bowman Gray School of
46 Leukemia
Medicine as a full member of the pediatric Oncology Group. Our accomplishments in the past grant period are described in detail in the proposal. Our institutional goals for the five year period of this grant include: (1) continuing our high level of patient accrual and excellent clinical contributions to the POG including our outstanding patient evaluability and protocol compliance which has merited a letter of commendation from the operations office at every 6-month analysis in the past (2) maintaining our institutional involvement in POG leukemia studies and our representation on the new ALL core committee (3) continuation and further development of our multi-disciplinary institutional commitment to POG Hodgkin's disease activities (4) a major role on the POG cytogenetics committee including optimal use of our new reference laboratory status (5) increased institutional development of late effects studies in collaboration with the POG late effects efforts (6) expansion of our efforts in neuro-oncology including increased enrollment on brain tumor studies and investigator roles on the POG brain tumor committee (7) use of in situ studies of tumor cell ploidy in collaboration with POG and other investigators (8) continued contributions to the administrative aspects of the POG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: CANCER CTR
PEDIATRIC
ONCOLOGY
GROUP--MIDWEST
CHILDREN'S
Principal Investigator & Institution: Camitta, Bruce M.; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2001; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The primary objective of the Midwest Children's Cancer Center is to reduce the incidence of and mortality from childhood cancers. This is approached by: 1) providing the best possible patient care (diagnostic and therapeutic; 2) education of medical and nonmedical groups as to the types of, treatments for, and availability of care for different childhood cancers; and 3) clinical and laboratory research. Investigators at the Cancer Center include specialists in pediatric oncology, surgery, orthopedic surgery, neurosurgery, radiology, radiation therapy, pathology, neurology, psychology and nursing. All new patients are discussed at a multidisciplinary Tumor Board. The children are then treated on Pediatric Oncology Group (POG) or institutional protocols. Results are analyzed and reported regularly. The purpose for the Midwest Children's Cancer Center's participation in POG are: l) to enhance the probability of achieving the above objectives by collaboration with other institutions in the design and execution of clinical protocols; and 2) to evaluate, through laboratory investigations, aspects of tumor biology which result in successful and unsuccessful therapy. Pediatric tumors are relatively rare. The POG is composed of more than 50 member institutions. By pooling resources, biologic and therapeutic studies on these uncommon tumors are facilitated. Similar collaboration permits more rapid development of new drugs. In addition, participation in a common milieu promotes dissemination of information between institutions and investigators. If all children with cancer receive the best possible care, morbidity and mortality will be minimized. The Midwest Children's Cancer Center has been a major contributor to POG by: 1) patient accrual; 2) coordination of POG protocols; 3) institutional pilot studies that were advanced to POG studies; and 4) participation in POG disease and administrative committees. In the next grant period we will continue each of these activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
47
Project Title: PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM Principal Investigator & Institution: Barredo, Julio C.; Professor; Pediatrics; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2001; Project Start 15-JUN-1996; Project End 31-DEC-2002 Summary: (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: PROJECT ALLIFE - EXERCISE AND LEUKEMIA SURVIVORS Principal Investigator & Institution: Oeffinger, Kevin Charles.; Family Practice and Cmty Med; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2007 Summary: (provided by applicant): Adult survivors of childhood leukemia are a growing population that have an excess in all-cause and cardiovascular (CVD)-related mortality and are at risk for multiple health problems, including CVD, osteoporosis, and obesity. Physical activity is protective and reduces risk for CVD, hypertension, Type 2 diabetes mellitus, and osteoporosis. The Lifestyle Physical Activity intervention has been efficacious in the general population in increasing sustainable levels of moderateintensity physical activity and cardiorespiratory fitness and improving cardiovascular risk profiles and mental health. A targeted intervention tailored to the needs of leukemia survivors and intended to increase sustainable levels of moderate-intensity physical activity is not only warranted, but critical. It is imperative that methods to reduce morbidity and mortality of this young population while enhancing quality of life and productivity be addressed. The proposed study, Project ALLIFE (Acute Leukemia Lifestyle Intervention For Everyday), is a 12- month effectiveness trial with 120 young adult survivors of childhood leukemia randomized to either the Lifestyle Physical Activity intervention (ALLIFE-I) or a standard control group who will receive a periodic generic health newsletter (ALLIFE-SC). Major data collections will be at baseline, 6- and 12-months, with the two primary outcomes being levels of physical activity, as measured by 7-day physical activity recall, and cardiorespiratory fitness, as measured by the Aerobic Adaptation Test. Secondary outcomes will include other well-established measures of physical activity, cardiovascular risk profiles, gait and balance assessment, and psychological measurements. The primary research hypothesis to be tested is that the Lifestyle intervention will significantly increase physical activity and
48 Leukemia
cardiorespiratory fitness in adult survivors of childhood leukemia in comparison with standard care. Three additional questions to be addressed are: determining if such an intervention leads to improvement in cardiovascular risk profile; determining if gait and balance disturbances are related to physical inactivity in leukemia survivors and if these disturbances improve with the intervention; and identifying factors that are predictive of improvement or lack of improvement in outcomes. This study will represent the first clinical trial aimed at increasing physical activity in leukemia survivors and will advance our understanding of this vulnerable population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: PROMYELOCYTIC LEUKEMIA PROTEINS ROLE IN APOPTOSIS Principal Investigator & Institution: Borden, Katherine L.; Associate Professr; Physiology and Biophysics; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-JAN-2004 Summary: (adapted verbatim from the investigator's abstract) The promyelocytic leukemia protein PML has been ascribed roles in growth control, transformation suppression and cell death but its mechanism of action is unknown. These functions are closely tied to the subcellular localization of the protein. In normal cells, the majority of PML forms nuclear bodies which are disrupted when the cell undergoes stress. A chromosomal translocation disrupts PML in acute promyelocytic leukemia (APL) patients resulting in loss of PML nuclear bodies. Disruption of PML's growth control and apoptotic action is thought to contribute to leukemogenesis. Most viruses have evolved mechanisms to bypass host cell defenses such as apoptosis in order to survive. Several viruses target PML bodies during infection. The investigator has studied the effect of a single stranded RNA virus on PML to better understand its physiological function. This virus, lymphocytic choriomeningitis virus (LCMV), is able to establish chronic infection in tissue culture: thus, LCMV must disrupt host cell mediates apoptosis. This establishes a system for the study of PML and its role in apoptosis. A single viral protein, Z, can translocate PML nuclear bodies to the cytoplasm. This translocation may cause the decreased propensity of infected cells to undergo cell death when serum deprived. The investigator has identified a previously unknown component of PML nuclear bodies, the ribosomal protein PO. This protein has a nuclear role in DNA repair, endonuclease activities and a cytoplasmic role in translation. PO is upregulated in colon polyps and tumors suggesting that its association with PML in the nucleus may be related to PML's apoptotic action. The investigator are involved in studying several novel aspects of PML function, in particular interactions with Z, PO and a novel proline rich homeodomain protein PRH and the function of PML in translation. The investigator hypothesizes that PML executes its pro-apoptotic actions through association with other cellular partners and that LCMV proteins block this activity. Because of the association with PML with ribosomal proteins like PO, they predict that PML is involved in translational control and that this action is linked to its pro-apoptotic function. They propose to: (1) determine other cellular partners of PML and assess whether these new partners affect PML's apoptotic action; (2) investigate the PML/Z interaction using high resolution NMR methods to elucidate that basis of this proline interaction motif; (3) determine whether PML is involved in translational control perhaps through interaction with PO and whether this action could be linked to PML's apoptotic action. Elucidating the molecular mechanism of action of PML has important implications for understanding the progression of APL and certain viral infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
49
Project Title: PROTEINASE 3 SPECIFIC IMMUNOTHERAPY OF LEUKEMIA Principal Investigator & Institution: Molldrem, Jeffrey J.; Chief, Section of Transplant Immunology; Blood & Marrow Transplantation; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-JAN-2003 Summary: A significant graft versus leukemia (GVL) immune response, mediated by donor lymphocytes after allogeneic bone marrow transplantation (BMT), contributes to the cure of 40-50 percent of adult patients with myeloid leukemias. However, allogeneic BMT is only available for 25 percent of all patients due to patient age and donor availability. Therefore, the overall objective of this proposal is to develop strategies for the generation of antigen-specific antileukemia immune responses for the treatment of myeloid leukemias that can be applied to more patients. Proteinase 3 (Pr3) is a 26kd myeloid-restricted azurophil granule protein that is normally maximally expressed only in developing promyelocytes and is an antigen for the antineutrophil cytoplasmic antibody (ANCA) in patients with Wegener's granulomatosis. Pr3 is overexpressed by 3 to 6 fold in 75 percent of chronic myeloid leukemia (CML) and 50 percent of acute myeloid leukemia (AML) cells. An HLA-A2-restricted 9 amino acid peptide derived from Pr3, PR1, has been shown to be a target epitope of cytotoxic lymphocytes (CTL) that preferentially lyse myeloid leukemia over normal bone marrow progenitors in vitro. The amount of CTL lysis correlates with Pr3 overexpression in the target cells. Detection of immunity to PR1 in normal donors and some patients with myeloid leukemia strongly implies that patient's own leukemia cells can act as a source of immunizing protein and begs the issue of whether existent immune responses to PR1 play any role in slowing leukemia progression and whether boosting of immune responses can offer any therapeutic benefit. The current NEW INVESTIGATOR proposal will assess the clinical importance of immune responses to PR1 peptide, evaluate a PR1 peptide-based tumor vaccine in patients with myeloid leukemia, and since Pr1 is the first tissue-restricted epitope identified, will investigate other unique HLA-A2-associated Pr3 peptides as leukemic-specific epitopes for CTL. To investigate the clinical significance of immune responses to PR1, CTL precursor (CTLP) frequency against PR1 will be determined in patients with CML, AML and their normal marrow donors before and after BMT using limiting dilution analysis and by using a fluorescence-tagged PR1-tetramer to directly label PR1-specific CTL. Pr3 expression in leukemia and the surface phenotype of leukemia and PR1-specific CTL will be examined and correlated to CTLP frequency and clinical outcomes. To investigate whether an immune response to PR1 can be boosted, a phase I/II study (NCI study number T98-0017, Molldrem P.I.) of PR1 peptide-based vaccine with incomplete Freund's adjuvant (IFA) will be conducted in patients with CML, AML, and myelodysplastic syndrome. The University of Texas M. D. Anderson Cancer Center has approved the investigation, and NCI will supply GMP quality PR1 peptide and IFA. Immune responses to the vaccine will be determined by LDA of CTLP and by analyzing the number of PR1-specific CTL with the fluorescent PR1-tetramer and will be correlated to clinical response and percent of leukemia blasts in bone marrow. Lastly, other synthetic HLA-A2-associated peptides from Pr3 will be investigated for their potential to elicit peptide-specific CTL from donor PBMC in vitro and then tested for ability to lyse myeloid leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
50 Leukemia
·
Project Title: RETINOID INDUCED APOPTOSIS IN LEUKEMIA CELLS Principal Investigator & Institution: Piedrafita, F Javier.; Sidney Kimmel Cancer Center San Diego, Ca 92121 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-JAN-2003 Summary: Retinoids have proven to be effective cancer preventive and chemotherapeutic agents. Retinoids can be used to alleviate acute promyelocytic leukemia in humans, leading to an apparent cure when combined with chemotherapy. However, effective retinoids for the treatment of other hematopoietic malignancies are not available yet. Retinoid signals are mediated by the retinoid receptors, RARs and RXRs, which belong to the steroid/thyroid hormone/retinoic acid superfamily of transcription factors. Recent evidences have shown that retinoids can induce apoptosis in certain cancer cell lines. Apoptosis is a naturally occurring form of cell death important for defense, development, homeostasis, and ageing, and alterations in the apoptosis pathways or functions contribute to the pathogenesis of certain human diseases, including cancer. Importantly, a novel class of selective retinoids has been recently discovered which are highly effective against a human non-small cell lung cancer in an animal model. These retinoids can induce apoptosis in certain cell lines, including several leukemia cell lines, and show promise as novel direct therapeutic agents for the treatment of cancer. They aim to investigate the mechanisms of action of these novel apoptosis inducing retinoids in leukemia cells. They will analyze the potential role of two transcription factors, Sp1 and NfkB, in retinoid-induce apoptosis. They have found that treatment of leukemia cell lines with those apoptotic retinoids causes loss of the DNA binding activity of both transcription factors: Sp1 is a target for caspases, while NfkB is translocated into the cytosol. They provide evidence that activation of caspases in necessary for retinoid-induced apoptosis. This is partially affected by inhibitors of protein synthesis. However, inhibition of RNA transcription has no effect on retinoid-induced apoptosis, suggesting a new mechanism of action for those novel retinoids which is independent of transcription. Thus, understanding the role of Sp1 cleavage and the mechanism of NfkB inhibition during retinoid-induced apoptosis will significantly enhance their knowledge of this novel retinoid action, and is likely to refine the future design and improve the development of new retinoids which would result in more effective treatments of leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: RETROVIRAL IMMUNOTOXINS FOR LEUKEMIA Principal Investigator & Institution: Vallera, Daniel A.; Professor; Therapeutic Radiology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2003 Summary: (Applicant's Abstract) Immunotoxins (IT) are experimental pharmacologic agents that are made by linking antibodies or cytokines that specifically bind to cancer cells to potent catalytic toxins of which a single molecule can kill a cell. The major purpose is to deliver therapy selectively to cancer cells instead of nontarget organs as does conventional chemotherapy. Although these agents selectively bind and kill cancer cells, clinically they have been limited by their 1) failure to penetrate and localize in adequate concentrations in cancer target tissue 2) localization in nontarget organs limiting the tolerated dose and collapsing the therapeutic window. In this application, the applicant will explore a solution to this problem. Cells of the immune system such as T cells are the most prominent cell types that penetrate, attack, and destroy cancer cells
Studies
51
and are naturally suited for the expression and production of cytokines in response to antigenic challenge. Therefore, he proposes using T cells to deliver retroviral IT (retIT) consisting of IL-4 spliced to genetically modified diphtheria toxin at the site of the leukemia cells. He has established a model of retIT therapy that he will use as a foundation for future attempts to modify and improve retIT. He will test the usefulness of retIT for therapy of myeloid leukemia, the most common adult form of leukemia. In this model, the applicant has produced an antigen specific CTL cell line called T15 by hyperimmunization with irradiated murine myeloid leukemia C1498. When T15 is transduced with retrovirus encoding IL-4 spliced to truncated DT, T15 cells have been shown to express and secrete IL-4 retIT which specifically kills IL-4R+ C1498 cells, but not IL-4R- cells in vitro. More importantly, mice given C1498 tumors show significantly enhanced anti-C1498 effects when treated with transduced T15 cells as compared to controls. In this application in the first aim, the applicant intends to use this model first to answer important questions regarding the role of IL-4 IT and T15 CTL in the first retroviral model. Is secretion of IL-4 IT necessary and how much must be secreted to get an anti-cancer effect? Does the amount of secreted retIT correlate with the magnitude of the anti-cancer effect? What is the role of the CTL vehicle in the retIT response? Can we enhance secretion and CTL delivery of retIT? In the second aim, he will determine if retIT administration has advantages over conventional IT administration particularly regarding their toxic effects on non-target organ systems and effects on the immune response. With the anti-C1498 effects that he has already established as a baseline, in the last aim he will ask whether or not important genetic modifications can improve retIT. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: ROLE TRANSFORMATION
OF
THE
PNH
PHENOTYPE
IN
LEUKEMIC
Principal Investigator & Institution: Bessler, Monica; Barnes-Jewish Hospital Ms 90-94212 St. Louis, Mo 63110 Timing: Fiscal Year 2001; Project Start 20-JAN-2001; Project End 31-DEC-2005 Summary: (adapted from the applicant's abstract): Paroxysmal nocturnal hemoglobinuria (PNH) is a blood disorder, which is caused by the clonal expansion of a hematopoietic progenitor cell that carries a somatic mutation in the X-linked PIGA gene. It presented classically with hemoglobinuria due to intravascular hemolysis, thrombotic complications, and pancytopenia. The PIGA gene encodes a protein subunit of a glycosyltransferase essential in the synthesis of glycosyl phosphatidylinositol (GPI) anchor molecules. Patients with PNH therefore have a proportion of blood cells deficient in all GPI-linked surface molecules. PNH is frequently found in patients with aplastic anemia (AA) and in patients with myelodysplasia (MDS). Although not a neoplastic disease on its own, patients with PNH have an increased risk of developing acute myeloid leukemia (AML). Promoted by the clinical association of PNH with AA, MDS, and AML, we raised the hypothesis that a PIGA gene mutation alone does not cause clonal expansion or leukemic transformation. But due to their inability to like certain proteins to the cell surface through a GPI-anchor PNH cells escape immuno surveillance and cell death that causes bone marrow aplasia in AA and controls neoplastic cell growth in early leukemogenesis. In the proposed research we will use a mouse model that closely mimics the human disease and investigate the association of PNH with MDS and AML. We will obtain mice with blood cells lacking GPI-linked proteins by disrupting the murine Piga gene in early hematopoietic progenitor cells in the bone marrow using the Cre-loxP system. By this approach we will generate two types of mice, one with all blood cells deficient in GPI-linked proteins whereas the other
52 Leukemia
will have both PIGA (+) and PIGA(-) circulating blood cells. We will then compare PIGA(+) and PIGA(-) hematopoiesis in these mice in vitro and in vivo under a variety of circumstances, including the administration of stimuli that trigger cell death along with agents known to cause leukemia transformation. Competition between cells expressing wild type Piga and those expressing the recombined Piga allele will enable us to uncover even subtle differences in cell death and proliferation in any stages of hematopoietic differentiation. These experiments will demonstrate whether PIGA(-) blood cells are more resistant to specific stimuli that activate apoptotic cell death and whether mice with PIGA(-) blood cells develop leukemia earlier and more frequent compared to mice with phenotypically normal blood cells. In this way we hope to identify the factors that differentially influence growth and death of PNH and normal hematopoietic progenitor cells and to elucidate mechanisms that may lead to leukemia transformation in patients with PNH. The availability of a mouse model for PNH will provide us with a powerful tool to test new therapeutic agents for the treatment of PNH, PNH/MDS, PNH,AML and possibly other clonal blood disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: SEQUENCE CHROMOSOMES
BASED
FISH
ANALYSIS
OF
PHILADELPHIA
Principal Investigator & Institution: Knoll, Joan H.; Children's Mercy Hosp (Kansas City, Mo) 2401 Gillham Rd Kansas City, Mo 64108 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant) One of the most prevalent abnormalities in leukemia patients, the Philadelphia chromosome, a translocation of the ABL1 oncogene on chromosome 9 to the BCR gene on chromosome 22, occurs in adult chronic myelogenous leukemia and childhood acute chronic leukemia. In addition to the translocation, the commercial ES-probe used in clinical cytogenetics laboratories sometimes detects deletions of DNA sequences upstream of the ABL1 gene on the derivative 9 chromosome (in 1/10 to 1/3 of patients). These deletions appear to be prognostic for early blast crisis. We hypothesize that these deletions result in hemizygosity of additional genes adjacent to ABLI. These deletion breakpoints can be refined with high- resolution fluorescence in situ studies (scFISH), which uses short single copy (sc) DNA probes designed from the draft genome sequence. Chromosomal preparations of patient specimens diagnosed with Philadelphia chromosomes in clinical cytogenetic laboratories will be analyzed with these probes. ScFISH, which has been developed in our laboratories, provides an unprecedented level of resolution for delineating sequences associated with inherited chromosomal rearrangements by FISH (Rogan, Cazcarro, Knoll, 2001; Knoll, Cazcarro, Rogan, 2000). We have developed and validated single copy DNA probes (quickly and without cloning) for FISH analysis of more than 20 distinct chromosomal regions. We aim (1) to develop scFISH probes for ABL1 oncogene, BCR and their adjacent regions from the draft genome sequence and verify their locations by FISH; (2) to compare results with scFISH probes to those obtained using the commercially available ES-probes for t(9;22) on the same patient specimens; and (3a) to categorize cytogenetically positive t(9;22) into molecular subgroups based on the sizes of deletion centromeric to ABL1 and the breakpoints within the BCR gene, (3b) to determine if there are preferential sites of breakage on chromosome 9 adjacent to ABL1, and to localize these sites. In contrast with scFISH probes, commercial reagents detecting this translocation routinely used in clinical laboratories comprise large multigenic segments. We anticipate that both the commercial and scFISH probes will detect the chromosomal translocation in some
Studies
53
patients, however, only the scFISH probes are expected to delineate deletions in sequences immediately adjacent to ABL 1, and to distinguish the major and minor sites of breakage in the BCR gene that correspond to chronic myelogenous leukemia and acute lymphocytic leukemia, respectively. The proposed study will delineate the chromosomal regions that undergo breakage in these types of leukemia and will establish whether there are common deletion breakage intervals on the translocated chromosome 9. Our long range goal is to classify patients based on the sites of translocation and deletion size, and then to determine if the disease complications can be attributed to the loss of specific genes adjacent to ABL1. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: SIGNALS DOWNSTREAM OF NOTCH REGULATING LYMPHOID CELL FATE AND FUNCTION Principal Investigator & Institution: Pear, Warren S.; Associate Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 13-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The human homologue of Notchl was originally identified at the chromosomal breakpoint in a recurrent chromosomal translocation in T-cell leukemia. We have previously shown that constitutive expression of activated Notchl causes T-cell leukemia in mice and that its role in leukemia may be related to its normal function in lymphoid development. As part of our long-term plan to understand the role of Notch in leukemia, we have initiated studies to understand Notch function in hematopoiesis. Notch proteins are a conserved family that regulates cell fate choice in many lineages, including stem cells. Recently, we have provided evidence that Notch plays a key role in regulating lymphoid cell fate decisions from hematopoietic stem cells. To further understand this process, we have undertaken studies to understand Notch function in B cell development. Our preliminary results suggest that Notch signaling promotes apoptosis of B cells and that inhibition of Notch signaling leads to B cell development at the expense of T cell development, both in vivo and in organ cultures. The proposed studies focus on the role of Notch signaling in B cell development and survival. In Specific Aim 1, we will focus on Deltex, a poorly understood modulator of Notch signaling. We have found that Deltex antagonizes Notch signaling in lymphoid progenitors and promotes B cell development from hematopoietic stem cells. The studies in this aim will use a combination of in vivo, organ culture, and in vitro methods to understand the function of this protein in lymphoid development. In Specific Aim 2, we will characterize Notch signaling in B lymphoid subsets and determine the mechanism by which Notch signaling specifically promotes B cell death. These studies will lead to an improved understanding of lymphoid development and function, and in doing so, will provide therapeutic insights into treating leukemia and other diseases of the immune and hematopoietic systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: STAT ACTIVATION IN LEUKEMIAS Principal Investigator & Institution: Zuckerman, Kenneth S.; Professor; Internal Medicine; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: (Applicant's Abstract) The first purpose of this project is to understand the molecular mechanisms responsible for the constitutive activation of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signal transduction
54 Leukemia
pathways in some cases of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML). The second purpose of this project is to determine the importance of constitutive JAK2/STAT5 activation in development and maintenance of the leukemic phenotype, both in vitro and in vivo. The primary hypotheses being tested are that specific activating mutations that lead to constitutive activation of JAK/STAT signal transduction pathways are responsible for the development and/or maintenance of leukemic cell survival and proliferation, and that, in leukemic cells expressing constitutively activated STAT5, inhibition of STAT5 activation or function. Three specific aims are proposed to test these hypotheses. Specific Aim 1 is to determine the mechanism(s) of constitutive activation in the HEL/Dami and Meg-01 human leukemic cell lines. Specific Aim 2 is to determine whether constitutive JAK/STAT signaling pathway activation plays an important role in maintenance of the leukemic phenotype of primary human AML cells. Specific Aim 3 is to determine the ability of double-stranded "decoy" oligonucleotides containing the STAT5 binding domain to inhibit the unregulated survival and proliferation of leukemic cells in vivo. The models to be tested include: (1) human HEL/Dami and Meg-01 cell lines implanted in sublethally irradiated NOD/SCID mice; (2) tet-off bcr/abl transgenic mice, which develop leukemia when mice are deprived of tetracycline in their drinking water (obtained from Dan Tenen); and (3) mice transplanted with bone marrow cells transfected with TEL/JAK2 or TEL/ABL retroviruses, which result in development of leukemias that have constitutively activated STAT5. These studies should lead to new understanding approaches for treatment of leukemias in which STAT activation plays a role in maintenance of the leukemic phenotype. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE Principal Investigator & Institution: Van Etten, Richard A.; Director, Hematologic Malignancies; Cbr Institute for Biomedical Research 800 Huntington Ave Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Adapted from the investigator's abstract) The human Philadelphia (Ph) chromosome-positive leukemias, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia, are among the most common hematological malignancies, and current therapy for these diseases is inadequate. Expression of the product of the t(9;22) Ph chromosome, the BCR!ABL fusion gene, in the hematopoietic system of mice by generation of transgenic mice or through retroviral transduction and transplantation of bone marrow has demonstrated that BCR/ABL is a leukemia specific oncogene and the direct cause of CML. The long term objective of this application is a more complete molecular and genetic understanding of the pathophysiology of human Ph-positive leukemias, particularly the myeloproliferative disease CML. These goals will be accomplished by the use of a retroviral bone marrow infection/transplantation mouse model system that accurately and quantitatively models both human CML and Ph-positive B-lymphoid leukemia, and will have two Specific Aims. In the first Aim, the signaling pathways important for leukemogenesis by BCR/ABL will be identified by testing BCR/ABL mutants, by further analysis of the requirement for direct binding of the Grb2 adapter protein by the Bcr/Abl fusion protein, and through the use of mice with germline mutations in signaling molecules. In the second Aim, the bone marrow target cells that initiate the CML-like disease and B-lymphoid leukemia induced by BCR/ABL will be characterized and isolated by physical and immunological methods. These investigations will add important new information to our understanding of these
Studies
55
leukemias, that would be difficult if not impossible to obtain from studies in vitro, in cultured cells, or in primary human CML cells. This knowledge will be valuable for improving the diagnosis and treatment of the Ph-positive leukemias. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: SUBNUCLEAR TARGETING OF TRANSCRIPTION FACTORS Principal Investigator & Institution: Stein, Gary S.; Professor and Chairman; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: Nuclear architecture is dramatically modified during hematopoietic differentiation, as well as during the onset and progression of leukemias. Project 2 addresses the hypothesis that fidelity of subnuclear targeting of the key hematopoietic regulatory factor AML-1 is abrogated by leukemia-related chromosomal translocations that delete specific intranuclear trafficking signals. We postulate that the misrouting of the gene regulatory factor is a dominant defect that causes deregulation of AMLmediated control of cell growth and differentiation. These investigators have shown that AML1 contains a 31 amino acid nuclear matrix targeting signal (NMTS) that facilitates trans-activation by mediating association with components of nuclear architecture which support transcription. Additionally, the applicant has demonstrated that the 8;21 chromosomal translocation in AML leukemia modifies intranuclear targeting of the AML-1 transcription factor. Thus, the specific aims are to: (i) characterize the subnuclear targeting signal in AML-1-1 by establishing the structural basis for and functional consequences of interactions with the nuclear matrix; (ii) determine the saturability and dynamics of intranuclear trafficking of AML-1 in hematopoietic cells in functional nuclear domains; (iii) assess the spatio- functional distribution of AM-1 and leukemia related AML-1 fusion proteins during cell growth and myeloid differentiation; (iv) examine the physiological consequences of subnuclear targeting for hematopoiesis by genetically ablating the NMTS in the murine AML-1 locus; and (v) define key protein/protein interactions which regulate intranuclear trafficking in hematopoietic cells by cloning the nuclear docking protein of AML-1. The results of the proposed studies will provide an in-depth understanding of the interrelationships between subnuclear targeting of gene regulatory factors, chromosomal translocations involving trafficking signals and modifications in gene expression characteristic of leukemias. GRANT-P01CA82834-01A2-0003 The long term objective of this work is to understand how centrosomes contribute to tumorigenesis. Centrosomes are poorly understood organelles required for organization of mitotic spindles and accurate segregation of chromosomes during cell division. Thus, centrosomes are critical players in the redistribution and reorganization of the genome as it is assembled into nascent nuclei following mitosis. There is no other single cellular event that has a greater impact on the quantity, composition and organization of chromatin within the nucleus. We recently made the striking observation that malignant tumors had increased levels of the centrosome protein pericentrin, abnormal centrosomes, aberrant mitotic spindles and missegregated chromosomes. Moreover, artificial elevation of pericentrin in normal cells induced nearly identical features including aneuploidy, a condition linked to tumor malignancy, metastasis and fatality. Pericentrin over-expression also appeared to abrogate the mitotic checkpoint that normally induces mitotic arrest in the presence of unattached chromosomes. Over- expressed pericentrin bound and mislocalized cytoplasmic dynein, a molecular motor known to function in spindle organization and possibly checkpoint control. Based on these observations, we propose a model in which centrosome defects contribute to tumorigenesis by causing improper segregation of the
56 Leukemia
genome and creating aneuploid cells. The discovery of centromsomes as potential contributors to malignant tumor progression provides us with a unique opportunity to elucidate a novel mechanism for tumorigenesis. The specific aims of this proposal are: 1. To determine whether proteins of the centrosome and nucleus are altered in tumors. 2. To test whether pericentrin has oncogenic potential. 3. To determine how elevated levels of pericentrin cause aneuploidy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: TARGETED MYELODYSPLASTIC S
INHIBITION
OF
ANGIOGENESIS
IN
Principal Investigator & Institution: List, Alan F.; Professor; University of Arizona P O Box 3308 Tucson, Az 857223308 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 31-DEC-2006 Summary: Description (provided by applicant) The MDSs represent some of the most common hematologic malignancies, with an incidence that approximates that for chronic lymphocytic leukemia. Given the aging of the United States population and the absence of a standard effective treatment for these disorders, management of patients with MUDS has become increasingly problematic. The MDSs share the distinguishing features of ineffective hematopoiesis and increased risk of leukemia transformation. Recent studies have shown that these disorders display an increase in bone marrow (EM) microvessel density, the magnitude of which directly correlates with myeloblast percentage. We have shown that vascular endothelial growth factor (VEGF) and its receptors are expressed by myelomonocytic precursors in MDS and acute myelogenous leukemia (AML), and that VEGF elaboration contributes to suppression of committed progenitor growth and excess medullary generation of TNF alpha. Using the VEGFreceptor competent KG-1 AML cells as a model, we have characterized the biologic effects of VEGF in AML cells, which include suppression of nuclear translocation of NEB, stimulation of leukemia self renewal via interaction with either of the Fit-1 or KDR VEGF receptors, and activation of the phosphoinositol-3-kinase/Akt signaling pathway. We propose that agents which modify cellular VEGF elaboration or VEGF receptor signaling will impair leukemia progenitor self renewal, lower resistance to maturation signals, impair generation of inflammatory cytokines, and promote more effective hematopoiesis in MDS. Our efforts to delineate the VEGF receptor signaling pathway in AML progenitors provides a unique opportunity to validate in vivo target inhibition as an endpoint for biologic activity of novel therapeutics. In this project, we will investigate three Specific Aims that evaluate novel therapeutics which inhibit the actions of VEGF or its receptor signaling in patients with MDS, and delineate the relationship between in vivo target inhibition, and biologic and hematologic endpoints. The Specific Aims of this proposal are: 1) To determine the biologic effects of the VEGF inhibitor, thalidomide, in patients with MDS, and the relationship between target inhibition and hematologic response. 2) To investigate the molecular and pharmacologic effects of the VEGF receptor tyrosine kinase inhibitor, SU-5416, in vitro and in animal models. 3)To determine the biological effects of SU-5416 in patients with MDS, and the relation between hematologic response and VEGF -receptor tyrosine kinase inhibition in clinical specimens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
·
57
Project Title: TARGETING FLT3 AS A NOVEL SPECIFIC THERAPY FOR LEUKEMIA Principal Investigator & Institution: Levis, Mark J.; Oncology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): Leukemia remains a deadly disease in both adults and children. The majority of patients still die, and new treatments are urgently needed. There is now substantial data indicating that the receptor tyrosine kinase FLT3 plays a role in a significant fraction of leukemias. FLT3, which is expressed in most cases of acute myeloid and acute lymphocytic leukemia (AML and ALL), is constitutively activated by internal tandem duplication (ITD) mutations of the juxtamembrane region, by point mutations in the kinase domain, and by co-expression of FLT3 ligand (FL). 30% or more of AML cases harbor an activating mutation of FLT3, and this subset of patients has been shown to have a worse prognosis. Preliminary data presented here provides evidence that a FLT3 tyrosine kinase inhibitor is specifically cytotoxic to AML cells harboring FLT3 activating mutations. This proposal's scientific objective is the development of a FLT3 tyrosine kinase inhibitor for use in the treatment of leukemia. The immediate goal is to characterize the responses of different types of leukemias to the inhibitors in order to predict which patients may benefit from this therapy. The specific aims will be to test human leukemia cell lines and primary leukemic blasts for cytotoxic response to FLT3 inhibitors, with and without chemotherapy, and to correlate this cytotoxic response with changes in downstream signaling proteins and gene expression. Similar correlative studies will be performed on samples from patients receiving the inhibitor as part of a clinical trial. A FLT3 inhibitor has tremendous potential as an alternative or adjunct to conventional therapy for acute leukemias. This proposal has two goals. The first is to address the urgent need for new leukemia therapies. The second is to allow the principal investigator, Dr. Mark Levis, to develop into a laboratory-based researcher whose focus is to translate basic science research into clinical applications. With the guidance of a mentor who has expertise in the pathogenesis of leukemia, along with a structured educational program and a supportive academic environment, the principal investigator will use the support provided by this award to complete the transition to independent clinician scientist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: TEL AND THE T(12--21) AND B CELL ALL Principal Investigator & Institution: Hiebert, Scott W.; Professor; Biochemistry; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2001; Project Start 01-AUG-1997; Project End 31-MAY-2002 Summary: The t(12;21) is the most frequent genetic abnormality associated with pediatric B-cell ALL, present in 25-30% of all cases. This translocation fuses the Nterminal 333 amino acids of TEL, a putative ets family transcription factor, to the DNA binding and transactivation domains of AML-lB, a transcription factor that is the target of multiple translocations in myeloid leukemia. Our preliminary work indicates that the addition of the N-terminal 3/4 of TEL to AML-lB converts AML-lB from an activator to a repressor of transcription. This proposal tests the hypothesis that the inhibition of AML- lB transcriptional activity by the t(12;21) fusion protein is a key event in leukemogenesis. Up to 90% of patients with the t(12;21), also have mutations in their second TEL allele. The high frequency of loss of TEL function suggests that TEL is a tumor suppressor and that its deletion cooperates with t( 12;21) in leukemogenesis.
58 Leukemia
Specific aim 1 will determine the molecular mechanism of TEL/AML- lB-mediated transcriptional regulation. These experiments will define both the mechanism of repression and the subdomains of TEL and AML-lB that bring about this repression. With this information, the factors that mediate these transcriptional effects can be identified. Specific aim 2 will test the hypothesis that TEL is a tumor suppressor by determining whether its overexpression inhibits cellular proliferation both in vitro and in vivo. In specific aim 3, transgenic mice will be engineered to inducibly express the t(12;21) fusion protein to examine whether TEL/AML-lB is a dominant interfering protein that induces leukemia, and whether its continuous expression is required to maintain the leukemic state. By crossing these mice with TEL-deficient mice, we will directly test whether the two lesions observed in the clinic cooperate in leukemogenesis. The experiments proposed will answer fundamental questions about the role of the t(12;21) in the generation and maintenance of leukemia and will provide a murine model for t 12;21 -associated leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: THE PLZF PROTEIN OF T(11;17)-PROMYELOCYTIC LEUKEMIA Principal Investigator & Institution: Licht, Jonathan D.; Professor and Vice Chairman; Ruttenberg Cancer Center; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2003; Project Start 01-APR-1993; Project End 31-JAN-2008 Summary: The promyelocytic leukemia zinc finger (PLZF) protein is a transcription factor, expressed in hematopoietic progenitor cells, fused to the retinoic acid receptoralpha (RAR alpha) in t(11;17)-associated acute promyelocytic leukemia (APL). Over the past 9 years, through two periods of funding, our group characterized t(11;17) APL as a distinct syndrome, unresponsive to retinoic acid. We determined that the PLZFRARalpha fusion generated in t(11;17) is a dominant negative form of PAR that actively recruits corepressors and histone deacteylase molecules to RAR target genes. The study of the PLZF fusion protein helped solidify the model of aberrant transcriptional repression as a pathogenic basis of leukemia. Though progress has been gratifying, many questions remain. The nature of the critical target genes of the retinoid receptor blocked by the fusion proteins of APL is not certain. The way in which genes are repressed is incompletely understood. Histone deacetylases are critically involved but other modes of chromatin modification, chromatin remodeling and epigenetic silencing of repressed genes are likely. The PLZF protein represses through a number of corepressors attracted though the BTB/POZ Domain. Further structure of this domain will yield further insights and potential therapeutic modalties in the disease. APL in animal models occurs after a considerable delay, indicating that other mutations are required for the disease to occur. One such cooperating mutation may be the mutation of the fit3 receptor tyrosine kinase molecule. One mode of cooperation may be the ability of the APL fusion proteins to abrogate the p53 pathway and prevent premature cellular senescence in response to activation of ras/map kinasse pathways. PML is a modulator of p53 function and PLZF may be as well. The proposed research will: 1. Determine of how PLZF controls myeloid cell growth and differentiation by elucidation of PLZF target genes which bind the PLZF protein in vitro and in vivo such as IL-6, cyclin A and other to be identified by whole genome PCR. 2. Define how an evolutionarily conserved protein motif, the POZ domain, functions in transcriptional regulation, though mutagensis of conserved residues and identification of partner proteins using the yeast two hybrid system. 3. Define protein-protein interaction networks that play a role in normal myelopoiesis and leukemogenesis (PML-PLZF, N-Cor-PLZF) 4. Extend
Studies
59
knowledge of gene regulation in early hematopoiesis through characterization of the cisacting sequences controlling expression of PLZF. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: THE ROLE OF CYCLIN A1 IN ACUTE MYELOID LEUKEMIA Principal Investigator & Institution: Wolgemuth, Debra J.; Professor; Obstetrics and Gynecology; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): We have identified a novel mammalian A-type cyclin, cyclin AI, that our targeted mutagenesis in mice revealed to be essential for the progression of male germ cells into meiosis. Human cyclin AI is also highly expressed in myeloid leukemia cell lines and in leukemic cells from patients with acute myeloid leukemias, in the promyelocytic form (APL) in particular. We have tested the hypothesis that the aberrant high levels of cyclin AI were causal in the leukemic phenotype, i.e., acting as an oncogene. Transgenic mice in which cyclin AI was expressed under the control of the human cathepsin G promoter in myeloid precursor cells were generated. They exhibited abnormal myelopoiesis and developed acute myeloid leukemia with low penetrance and long latency. Interestingly, in the transgenic mouse model and in human NB4 cells, the localization of cyclin A1 is predominantly cytoplasmic, distinct from its nuclear localization in germ cells. We wish to understand the cellular mechanisms in myelopoiesis that are altered in the presence of elevated levels of cyclin A1 that is now mostly cytoplasmic. The distinct cytoplasmic localization of cyclin A1 will be studied, testing the hypothesis that this property contributes to the tumorigenesis. We will also address the role of cyclin A1 during normal hematopoiesis by studying hematopoietic parameters in mice that are null for the cyclin A1 gene. The hypothesis that cyclin A1 will have distinct Cdk partners, other interacting partners, and substrates in normal versus leukemic cells will be tested using immunoprecipitation and a yeast 2-hybrid screen. As high levels of cyclin A1 protein have been shown to be characteristic of APL, we will ask whether manipulating the expression of cyclin A1 will affect the development of the leukemia. We will test this idea by performing genetic studies in which we will manipulate the expression of cyclin A1 in the fusion oncogene X-RARalpha transgenic animal models of APL. The question is whether these mice will be more resistant to the development of leukemia in the absence of cyclin AI. These studies will provide important insight into the etiology of myeloid leukemia, the role of cell cycle control in the oncogenic process, and the development of new and potentially highly tissue-specific target molecules for pharmacologic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: THE TRANSFORMING PROPERTIES OF THE MEIS1 GENE FAMILY Principal Investigator & Institution: Buchberg, Arthur M.; Associate Professor; Microbiology and Immunology; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: (Adapted from the investigator's abstract) BXH-2 mice develop a high incidence of myeloid leukemia that is causally associated with the expression of an ecotropic murine leukemia virus (MuLV). The MuLVs act as insertional mutagens to alter the expression of cellular protooncogenes or tumor suppressor genes that contribute to leukemia. Dr. Buchberg has identified a new common site of integration, Meis1 (Myeloid ecotropic viral integration site 1), in BXH-2 myeloid tumors. Sequence
60 Leukemia
analysis of Meis 1 reveals it to be a novel homeobox gene: the homeodomain of Meis1 is related to the PBX homeodomain family. PBX1 was identified as a Hox cofactor, cooperatively interacting with a subset of Hox genes in specifying its DNA target. Recent evidence has demonstrated that Meis1 can interact with a number of other homeodomain containing proteins, including a subset of Hox proteins, as well as Pbx1. This interaction, in some instances, results in the increased stabilization of protein-DNA complexes and is required for the nuclear localization of PBX proteins. The specific aims of this proposal are designed to understand how Meis1 cooperates with its partners to contribute to transformation. Specifically, Dr. Buchberg will dissect the interaction between Meis1 and other homeodomain containing proteins by both in vitro and in vivo assays. These aims will ultimately identify the domains required for transformation in a bioassay and correlate physical interactions with biological interactions. Moreover, using the yeast-two hybrid assay and protein pull-down assays, additional proteins will be identified that interact with the various spliced forms of Meis1, to begin the functional dissection of the alternative forms of Meis1. The goals of this proposal are to understand the molecular basis of cellular transformation mediated by Meis1. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: TOPOISOMERASE I INHIBITORS IN LEUKEMIA AND SOLID TUMORS Principal Investigator & Institution: Kaufmann, Scott H.; Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001; Project Start 01-APR-1997; Project End 31-MAR-2005 Summary: (Applicant's Abstract) Two topoisomerase I (topo I) poisons, topotecan (TPT) and irinotecan (CPT-l1), are currently licensed for use in the U.S. Clinical responses to these agents are highly variable. Although preclinical studies have identified numerous factors that can affect the action of topo I poisons in vitro, few of these parameters have been examined in tumor samples or correlated with clinical response. Studies supported by this grant have investigated 1) mechanisms of resistance to topo I poisons in clinical leukemia specimens and 2) effects of combining topo I poisons with other agents. In pursuing the first goal, we have demonstrated during the current funding period that topo I content in acute myelogenous leukemia specimens varies widely but correlates with other markers of proliferation (e.g., PCNA); that the TPT concentration required to stabilize topo I-DNA complexes in acute leukemia specimens ex vivo varies over a 30fold range irrespective of topo I content; and that this variation in TPT concentration required to stabilize topo I-DNA cleavage complexes can been recapitulated in a tissue culture model. Additional tissue culture studies have demonstrated enhanced sensitivity to TPT or SN-38 (the active metabolite of CPT-11) when activity of the DNA damage checkpoint kinase ATR is inhibited. While addressing the second goal, we have demonstrated that cytotoxic effects are more than additive when SN-38 is combined with the quinazoline-based kinase inhibitor CI1033 or with gemcitabine. Further studies have demonstrated that the SN-38/CI1033 synergy reflects enhanced drug accumulation as a result of CI1033-mediated inhibition of the ABC cassette transporter BCRP. To build on these results, we now propose to 1) evaluate the relationship between response of three well-defined cohorts of solid tumor patients receiving single-agent CPT-11 or TPT and various tumor cell parameters that have been implicated in drug resistance in preclinical models (including topo I content, p53 status, proliferative index, levels of anti-apoptotic Bcl-2 family members, and expression of replication checkpoint proteins); 2) use the recently developed tissue culture model to determine the mechanistic basis for the observation that different TPT concentrations are required to stabilize topo I-DNA
Studies
61
complexes in different leukemia specimens; and 3) examine the mechanistic basis for the unanticipated synergy of the gemcitabine + SN-38 combination and determine the effect of combining SN-38 with other agents currently undergoing early clinical testing. Collectively, these studies should provide insight into factors that affect response to topo I poisons in the clinical setting and aid in the rational integration of topo I poisons into multidrug regimens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: TREATMENT OF BCR/ABL CAUSED LEUKEMIAS WITH FTIS Principal Investigator & Institution: Heisterkamp, Nora C.; Associate Professor; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: The Bcr/Abl oncoprotein causes the development of Ph-chromosomepositive leukemias. Bcr/Abl P210 and P190 share a domain of Abi which encodes a deregulated tyrosine kinase. This activity perturbs a number of downstream signal transduction pathways including that of the small GTPase Ras. Inhibitors of the enzyme farnesyltransferase (FTIs) have been tested as possible therapeutic agents against Rasassociated solid tumors in man. We have generated a transgenic mouse model which clinically mimics Ph-positive acute lymphoblastic leukemia and tested the potential therapeutic properties of an FTI in this model. Our data show that FTIs are surprisingly potent in preventing the emergence of overt leukemia in our mice. We therefore hypothesize that Ffls are effective in the treatment of Bcr/AbI caused leukemias by interfering with specific small CTPases necessary for disease progression. We will explore this by determining which cellular characteristics known to be altered by Bcr/AbI expression including apoptosis, cytokine independence, mitogenesis and adhesion are affected by the FTIs in BaF3 lymphoid cells with regulatable Bcr/Abl expression. It will also be investigated which small GTPases including Ras are activated by Bcr/Abl in cell line and animal models, and which are targeted by treatment with the FTIs. In addition, we will evaluate whether the FTls are effective against terminal-stage disease in the Bcr/AbI P190 transgenic mouse model, whether they can cure P190caused leukemia/lymphoma in a bone marrow transplant model and whether Bcr/Ablexpressing cells develop resistance to FTIs. By utilizing a compound which apparently acts on downstream targets of Bcr/Abl in vivo, these experiments will provide unique insights into the mechanisms by which Bcr/AbI causes leukemia. These studies will also help pinpoint which pathway(s) are critical in transducing the oncogenic signals of Bcr/Abl, which could provide additional targets for therapeutic intervention. Finally, data will emerge which will be invaluable in the assessment nf Using FTIs in the treatment nf Ph-positive leukemia in man Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
·
Project Title: TREATMENT OF CHILDHOOD CANCER Principal Investigator & Institution: Brecher, Martin L.; Roswell Park Cancer Institute Corp Buffalo, Ny 14263 Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: Cooperative trials in pediatric cancer patients have played a major role in the remarkable improvement in cure of childhood cancers. Because most childhood cancers are rare, it is only through this mechanism that adequate numbers of patients can be accrued in reasonable lengths of time for randomized controlled studies. The Department of Pediatrics at Roswell Park Cancer Institute (RPCI) has actively
62 Leukemia
participated in cooperative group trials via the Pediatric Oncology Group (POG) to answer treatment questions which would be impossible to answer were we to conduct only single institution studies. Some pediatric solid tumors are so rare that national intergroup studies are required. We also participate in these intergroup studies. RPCI investigators are coordinators for a number of POG protocols including front-line studies for the treatment of advanced Hodgkin's disease, advanced small non- cleaved cell lymphoma, non-rhabdomyosarcoma soft tissue sarcomas, acute lymphoblastic leukemia in relapse, the National Wilms Tumor Study, brain tumors in infants, and the Intergroup Ewing's Sarcoma Study. Roswell Park investigators have also developed POG phase II studies of continuous infusion 5-fluouracil and the combination of cisplatin, ifosfamide and etoposide. Roswell Park investigators chair the Wilms Tumor Committee, the Neuroscience Subcommittee of the Brain Tumor Committee, and cochair the Pathology Discipline Core Committee, as well as being active on a number of other POG Core Committees. They have made major contributions over the last few years in the areas of solid tumor oncology, neuro- oncology and the treatment of lymphoid malignancies. We are strongly committed to the interdisciplinary approach to pediatric cancer and have established collaboration with the necessary clinical specialties including Radiation Medicine, Pediatric Surgery, Pediatric Neurology, Neurosurgery, and Orthopedic Surgery, as well as with researchers in immunology, pharmacology and molecular biology. As more children are cured of their cancers, the identification and prevention, when feasible, of complications of therapy have become imperative. We have been a major contributor to the identification and understanding of the long-term medical and psychosocial effects of the treatment of leukemia, Hodgkin's disease, and a number of solid tumors, both through the cooperative group mechanism and through institutional studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: TUMOR SUPPRESSORS HEMATOPOIESIS AND LEUKEMIA Principal Investigator & Institution: Amatruda, James F.; Children's Hospital (Boston) Boston, Ma 021155737 Timing: Fiscal Year 2001; Project Start 13-AUG-1999; Project End 31-JUL-2004 Summary: Hematopoiesis and leukemogenesis are developmental phenomena, in which complex interactions of multiple genes give rise to orderly differentiation or to maturation arrest and uncontrolled proliferation. While many of the terminal events in these pathways have been elucidated by cellular, biochemical and transgenic mouse studies, the genes responsible for the most fundamental developmental decisions in hematopoiesis and leukemogenesis have been less well-defined. Tumor suppressor genes (TSGs), first identified in hereditary human cancers, are likely to be among this group of fundamental genes. TSGs are key elements of cellular pathways that regulate growth and differentiation. Specific TSGs have been shown to be mutated or deleted in primary human leukemias and leukemic cell lines. Mouse knock-out models and patients deficient in several of these genes demonstrate defective hematopoiesis or develop leukemias. To better understand the function of tumor suppressor genes in normal hematopoiesis and leukemogenesis we have chosen as a model the zebrafish (Danio rerio), a vertebrate system that combines physiology and development with powerful genetics. We plan to create zebrafish strains deficient in known TSGs and to characterize hematopoietic defects and the development of leukemia in these strains. A suppressor or enhancer screen for mutations that correct the defects or cure the leukemia will lead to the isolation of additional genes in these pathways. The experiments described in this proposal are likely to identify novel proteins that play key
Studies
63
roles in the control of hematopoiesis and the genesis of leukemia. These proteins will be potential therapeutic targets for the treatment of aplastic anemia, myelodysplasia and leukemia in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen ·
Project Title: WUMC-CANCER AND LEUKEMIA GROUP B Principal Investigator & Institution: Bartlett, Nancy L.; Internal Medicine; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 08-MAY-1998; Project End 31-MAR-2009 Summary: (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National
3
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
64 Leukemia
Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “leukemia” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for leukemia in the PubMed Central database: ·
[gamma][delta] + T-Lymphocyte Cytotoxicity against Envelope-Expressing Target Cells Is Unique to the Alymphocytic State of Bovine Leukemia Virus Infection in the Natural Host. by Lundberg P, Splitter GA.; 2000 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=116339
·
11q23 Translocations Split the "AT-Hook" Cruciform DNA-Binding Region and the Transcriptional Repression Domain from the Activation Domain of the MixedLineage Leukemia (MLL) Gene. by Zeleznik-Le NJ, Harden AM, Rowley JD.; 1994 Oct 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45071
·
A bcr-3 isoform of RAR[alpha]-PML potentiates the development of PMLRAR[alpha]-driven acute promyelocytic leukemia. by Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ.; 1999 Dec 21; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24780
·
A Lymphokine, Provisionally Designated Interleukin T and Produced by a Human Adult T-Cell Leukemia Line, Stimulates T-Cell Proliferation and the Induction of Lymphokine-Activated Killer Cells. by Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA.; 1994 May 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43904
·
A Lysine-to-Arginine Change Found in Natural Alleles of the Human T-Cell Lymphotropic/Leukemia Virus Type 1 p12I Protein Greatly Influences Its Stability. by Trovato R, Mulloy JC, Johnson JM, Takemoto S, de Oliveira MP, Franchini G.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112727
·
A Moloney Murine Leukemia Virus-Based Retrovirus with 4070A Long Terminal Repeat Sequences Induces a High Incidence of Myeloid as Well as Lymphoid Neoplasms. by Wolff L, Koller R, Hu X, Anver MR.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=152129
·
A multistep process of leukemogenesis in Moloney murine leukemia virus-infected mice that is modulated by retroviral pseudotyping and interference. by Lavignon M, Evans L.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190262
4
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
65
·
A Novel Ubiquitin-Specific Protease, UBP43, Cloned from Leukemia Fusion Protein AML1-ETO-Expressing Mice, Functions in Hematopoietic Cell Differentiation. by Liu LQ, Ilaria R Jr, Kingsley PD, Iwama A, van Etten RA, Palis J, Zhang DE.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84097
·
A PMLRAR[alpha] transgene initiates murine acute promyelocytic leukemia. by Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM.; 1997 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20126
·
A Point Mutation in the N-Terminal Coiled-Coil Domain Releases c-Fes Tyrosine Kinase Activity and Survival Signaling in Myeloid Leukemia Cells. by Cheng HY, Schiavone AP, Smithgall TE.; 2001 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87334
·
A Yeast Artificial Chromosome-Based Map of the Region of Chromosome 20 Containing the Diabetes-Susceptibility Gene, MODY1, and a Myeloid Leukemia Related Gene. by Stoffel M, Beau MM, Espinosa R, Bohlander SF, Paslier DL, Cohen D, Xiang K, Cox NJ, Fajans SS, Bell GI.; 1996 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39463
·
Aberrant B cell receptor signaling from B29 ( Ig[beta], CD79b) gene mutations of chronic lymphocytic leukemia B cells. by Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ.; 2000 May 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25858
·
Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO. by Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=109300
·
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34 + cell proliferation: BCR /ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. by Jiang Y, Zhao RC, Verfaillie CM.; 2000 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27060
·
Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. by Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ.; 2000 Nov 21; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27220
·
Acrophialophora fusispora Brain Abscess in a Child with Acute Lymphoblastic Leukemia: Review of Cases and Taxonomy. by Al-Mohsen IZ, Sutton DA, Sigler L, Almodovar E, Mahgoub N, Frayha H, Al-Hajjar S, Rinaldi MG, Walsh TJ.; 2000 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87638
·
Activation of c-myb is an Early Bone-Marrow Event in a Murine Model for Acute Promonocytic Leukemia. by Nason-Burchenal K, Wolff L.; 1993 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45926
66 Leukemia
·
Activation of EVI1 Gene Expression in Human Acute Myelogenous Leukemias by Translocations Spanning 300-400 Kilobases on Chromosome Band 3q26. by Morishita K, Parganas E, Willman CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN.; 1992 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48987
·
Acute leukemia with promyelocytic features in PML /RAR[alpha] transgenic mice. by He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP.; 1997 May 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24673
·
Acute Leukemias of Different Lineages Have Similar MLL Gene Fusions Encoding Related Chimeric Proteins Resulting from Chromosomal Translocation. by Corral J, Forster A, Thompson S, Lampert F, Kaneko Y, Slater R, Kroes WG, van der Schoot CE, Ludwig W, Karpas A, Pocock C, Cotter F, Rabbitts TH.; 1993 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47392
·
Acute Mixed-Lineage Leukemia t(4;11)(q21;q23) Generates an MLL-AF4 Fusion Product. by Domer PH, Fakharzadeh SS, Chen C, Jockel J, Johansen L, Silverman GA, Kersey JH, Korsmeyer SJ.; 1993 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47247
·
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. by Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S, Kern W, Hiddemann W, Eils R, Haferlach T.; 2002 Jul 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126615
·
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. by Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ.; 2002 Jul 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123164
·
AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23). by Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y.; 1999 Dec 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24471
·
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. by Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, Pandolfi PP, Wolgemuth DJ.; 2001 Jun 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34442
·
Amino-Terminal Protein-Protein Interaction Motif (POZ-Domain) is Responsible for Activities of the Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor-[alpha] Fusion Protein. by Dong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong H, Wang Z, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen S.; 1996 Apr 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39661
·
AML1 /ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. by Miyamoto T, Weissman IL, Akashi K.; 2000 Jun 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16578
Studies
67
·
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. by Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE.; 2001 Aug 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=56972
·
An Antisense Oligodeoxynucleotide Targeted Against the Type II[beta] Regulatory Subunit mRNA of Protein Kinase Inhibits cAMP-Induced Differentiation in HL-60 Leukemia Cells Without Affecting Phorbol Ester Effects. by Tortora G, Clair T, ChoChung YS.; 1990 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53334
·
An Enhancer Variant of Moloney Murine Leukemia Virus Defective in Leukemogenesis Does not Generate Detectable Mink Cell Focus-Inducing Virus in vivo. by Brightman BK, Rein A, Trepp DJ, Fan H.; 1991 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51211
·
An ets-Related Gene, ERG, is Rearranged in Human Myeloid Leukemia with t(16;21) Chromosomal Translocation. by Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, Hayashi Y, Ohira M, Asano S, Ohki M.; 1993 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47758
·
An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. by Vilpo JA, Vilpo LM, Szymkowski DE, O'Donovan A, Wood RD.; 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231955
·
Analysis of p53 Inactivation in a Human T-Cell Leukemia Virus Type 1 Tax Transgenic Mouse Model. by Portis T, Grossman WJ, Harding JC, Hess JL, Ratner L.; 2001 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=114802
·
Analysis of the Disease Potential of a Recombinant Retrovirus Containing Friend Murine Leukemia Virus Sequences and a Unique Long Terminal Repeat from Feline Leukemia Virus. by Nishigaki K, Hanson C, Thompson D, Yugawa T, Hisasue M, Tsujimoto H, Ruscetti S.; 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=135779
·
Antileukemia effect of c-myc N3[prime prime or minute][right arrow]P5[prime prime or minute] phosphoramidate antisense oligonucleotides in vivo. by Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B.; 1997 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20551
·
Antiviral Activity of Shiga Toxin 1: Suppression of Bovine Leukemia Virus-Related Spontaneous Lymphocyte Proliferation. by Ferens WA, Hovde CJ.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98349
68 Leukemia
·
Apoptosis and Interleukin 7 Gene Expression in Chronic B-Lymphocytic Leukemia Cells. by Long BW, Witte PL, Abraham GN, Gregory SA, Plate JM.; 1995 Feb 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42530
·
Appearance of Mink Cell Focus-Inducing Recombinants during In Vivo Infection by Moloney Murine Leukemia Virus (M-MuLV) or the Mo +PyF101 M-MuLV Enhancer Variant: Implications for Sites of Generation and Roles in Leukemogenesis. by Lander JK, Chesebro B, Fan H.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112626
·
Approach to a Retrovirus Vaccine: Immunization of Mice Against Friend Virus Disease with a Replication-Defective Friend Murine Leukemia Virus. by Ruan K, Lilly F.; 1992 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50727
·
Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor [alpha] Oncoprotein Found in Human Acute Promyelocytic Leukemia. by Hong SH, Yang Z, Privalsky ML.; 2001 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=99892
·
Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. by Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H.; 1997 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20553
·
Association of CYP 3A4 genotype with treatment-related leukemia. by Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR.; 1998 Oct 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23750
·
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. by Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C.; 1999 Oct 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23105
·
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. by Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrozek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de la Chapelle A.; 2001 Nov 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=61139
·
Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. by Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF.; 1997 Dec 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28413
·
Bacteremia Due to a Novel Microbacterium Species in a Patient with Leukemia and Description of Microbacterium paraoxydans sp. nov. by Laffineur K, Avesani V, Cornu G, Charlier J, Janssens M, Wauters G, Delmee M.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154712
Studies
69
·
Biological Characteristics of the Leukemia-Associated Transcriptional Factor AML1 Disclosed by Hematopoietic Rescue of AML1-Deficient Embryonic Stem Cells by Using a Knock-in Strategy. by Okuda T, Takeda K, Fujita Y, Nishimura M, Yagyu S, Yoshida M, Akira S, Downing JR, Abe T.; 2000 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85087
·
Blast Crisis in a Murine Model of Chronic Myelogenous Leukemia. by Daley GQ, Etten RA, Baltimore D.; 1991 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53129
·
Both wild-type and strongly attenuated bovine leukemia viruses protect peripheral blood mononuclear cells from apoptosis. by Dequiedt F, Hanon E, Kerkhofs P, Pastoret PP, Portetelle D, Burny A, Kettmann R, Willems L.; 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191094
·
Bovine Leukemia Virus Structural Gene Vectors Are Immunogenic and Lack Pathogenicity in a Rabbit Model. by Kucerova L, Altanerova V, Altaner C, BorisLawrie K.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112833
·
Bovine Leukemia Virus SU Protein Interacts with Zinc, and Mutations within Two Interacting Regions Differently Affect Viral Fusion and Infectivity In Vivo. by Gatot JS, Callebaut I, Van Lint C, Demonte D, Kerkhofs P, Portetelle D, Burny A, Willems L, Kettmann R.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=155115
·
Bovine Leukemia Virus-Induced Lymphocytosis and Increased Cell Survival Mainly Involve the CD11b + B-Lymphocyte Subset in Sheep. by Chevallier N, Berthelemy M, Le Rhun D, Laine V, Levy D, Schwartz-Cornil I.; 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=109673
·
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. by Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ.; 1999 Aug 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17888
·
Calorie restriction reduces the incidence of myeloid leukemia induced by a single whole-body radiation in C3H /He mice. by Yoshida K, Inoue T, Nojima K, Hirabayashi Y, Sado T.; 1997 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20137
·
Calorie Restriction Suppresses Subgenomic Mink Cytopathic Focus-Forming Murine Leukemia Virus Transcription and Frequency of Genomic Expression While Impairing Lymphoma Formation. by Shield BA, Engelman RW, Fukaura Y, Good RA, Day NK.; 1991 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53089
70 Leukemia
·
Case of Catheter Sepsis with Ralstonia gilardii in a Child with Acute Lymphoblastic Leukemia. by Wauters G, Claeys G, Verschraegen G, De Baere T, Vandecruys E, Van Simaey L, De Ganck C, Vaneechoutte M.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88595
·
CD4-T-Cell Antigen Receptor Complexes on Human Leukemia T Cells. by Chuck RS, Cantor CR, Tse DB.; 1990 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54253
·
CD5 Is Dissociated from the B-Cell Receptor in B Cells from Bovine Leukemia VirusInfected, Persistently Lymphocytotic Cattle: Consequences to B-Cell ReceptorMediated Apoptosis. by Cantor GH, Pritchard SM, Dequiedt F, Willems L, Kettmann R, Davis WC.; 2001 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=114078
·
CD8 + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. by Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR.; 1999 Jul 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17569
·
Cell death induction by the acute promyelocytic leukemia-specific PML /RAR[alpha] fusion protein. by Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG.; 1997 Sep 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23524
·
Cellular pathways involved in the ex vivo expression of bovine leukemia virus. by Kerkhofs P, Adam E, Droogmans L, Portetelle D, Mammerickx M, Burny A, Kettmann R, Willems L.; 1996 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190055
·
Characteristics of Erythroleukemia Cells Selected for Vincristine Resistance That Have Accelerated Inducer-Mediated Differentiation. by Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks PA.; 1991 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51085
·
Characterization of a High-Molecular-Weight Notch Complex in the Nucleus of Notchic-Transformed RKE Cells and in a Human T-Cell Leukemia Cell Line. by Jeffries S, Robbins DJ, Capobianco AJ.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=133837
·
Characterization of a Polytropic Murine Leukemia Virus Proviral Sequence Associated with the Virus Resistance Gene Rmcf of DBA/2 Mice. by Jung YT, Lyu MS, Buckler-White A, Kozak CA.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=155147
Studies
71
·
Chronic Lymphocytic Leukemia Cells with Allelic Deletions at 13q14 Commonly have One Intact RB1 Gene: Evidence for a Role of an Adjacent Locus. by Liu Y, Szekely L, Grander D, Soderhall S, Juliusson G, Gahrton G, Linder S, Einhorn S.; 1993 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47425
·
Chronic myelogenous leukemia shapes host immunity by selective deletion of highavidity leukemia-specific T cells. by Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM.; 2003 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151894
·
Chronic Myeloproliferative Disease Induced by Site-Specific Integration of Abelson Murine Leukemia Virus-Infected Hemopoietic Stem Cells. by Han X, Wong PM, Chung S.; 1991 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52881
·
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. by Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.; 2002 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125018
·
Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes. by Yu M, Tong JH, Mao M, Kan LX, Liu MM, Sun YW, Fu G, Jing YK, Yu L, Lepaslier D, Lanotte M, Wang ZY, Chen Z, Waxman S, Wang YX, Tan JZ, Chen SJ.; 1997 Jul 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23834
·
Cloning of ELL, a Gene that Fuses to MLL in a t(11;19)(q23;p13.1) in Acute Myeloid Leukemia. by Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD.; 1994 Dec 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45386
·
Clustering of Syk is sufficient to induce tyrosine phosphorylation and release of allergic mediators from rat basophilic leukemia cells. by Rivera VM, Brugge JS.; 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230382
·
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. by Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, Alyea EP, Kantoff P, Soiffer RJ, Dranoff G, Ritz J.; 2001 Jun 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34696
·
Combined expression of pT[alpha] and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. by Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC, Frati L, von Boehmer H, Gulino A, Screpanti I.; 2002 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122602
72 Leukemia
·
Complete Bovine Leukemia Virus (BLV) Provirus Is Conserved in BLV-Infected Cattle throughout the Course of B-Cell Lymphosarcoma Development. by Tajima S, Ikawa Y, Aida Y.; 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=110004
·
Conditional Expression of the Ubiquitous Transcription Factor MafK Induces Erythroleukemia Cell Differentiation. by Igarashi K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M.; 1995 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41356
·
Constitutive retinoid receptors expressed from adenovirus vectors that specifically activate chromosomal target genes required for differentiation of promyelocytic leukemia and teratocarcinoma cells. by Lipkin SM, Grider TL, Heyman RA, Glass CK, Gage FH.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190771
·
Core Binding Factor [beta]--Smooth Muscle Myosin Heavy Chain Chimeric Protein Involved in Acute Myeloid Leukemia Forms Unusual Nuclear Rod-Like Structures in Transformed NIH 3T3 Cells. by Wijmenga C, Gregory PE, Hajra A, Schrock E, Ried T, Eils R, Liu PP, Collins FS.; 1996 Feb 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39993
·
Cutaneous Infection Caused by Cylindrocarpon lichenicola in a Patient with Acute Myelogenous Leukemia. by Iwen PC, Tarantolo SR, Sutton DA, Rinaldi MG, Hinrichs SH.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87389
·
Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia. by Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G.; 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88796
·
DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. by Fu GK, Grosveld G, Markovitz DM.; 1997 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19999
·
Deregulated expression of TCL1 causes T cell leukemia in mice. by Virgilio L, Lazzeri C, Bichi R, Nibu KI, Narducci MG, Russo G, Rothstein JL, Croce CM.; 1998 Mar 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19932
·
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. by Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ, Felix CA.; 2000 Mar 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16012
·
Development of Leukemia in Mice Transgenic for the tax Gene of Human T-Cell Leukemia Virus Type I. by Grossman WJ, Kimata JT, Wong F, Zutter M, Ley TJ, Ratner L.; 1995 Feb 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42636
Studies
73
·
Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. by Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD.; 2000 Apr 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18311
·
Dietary flavonoids and the MLL gene: A pathway to infant leukemia? by Ross JA.; 2000 Apr 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34309
·
Discordance between Bovine Leukemia Virus Tax Immortalization In Vitro and Oncogenicity In Vivo. by Twizere JC, Kerkhofs P, Burny A, Portetelle D, Kettmann R, Willems L.; 2000 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=102026
·
Disruption of Hematopoiesis and Thymopoiesis in the Early Premalignant Stages of Infection with SL3-3 Murine Leukemia Virus. by Rulli K, Lenz J, Levy LS.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=135944
·
Dissecting the Immune Response to Moloney Murine Sarcoma/Leukemia VirusInduced Tumors by Means of a DNA Vaccination Approach. by Milan G, Zambon A, Cavinato M, Zanovello P, Rosato A, Collavo D.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104473
·
Disseminated Infection Caused by Scedosporium prolificans in a Patient with Acute Multilineal Leukemia. by de Batlle J, Motje M, Balanza R, Guardia R, Ortiz R.; 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86531
·
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF -RAR[alpha] and NPM --RAR[alpha]. by Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, Xiong SM, Zhu J, Guo WM, Chen JQ, Xu SF, So E, Chan LC, Waxman S, Zelent A, Chen GQ, Dong S, Liu JX, Chen SJ.; 1999 May 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26879
·
DNA Methylation Profiles in the Human Genes for Tumor Necrosis Factor [alpha] and [beta] in Subpopulations of Leukocytes and in Leukemias. by Kochanek S, Radbruch A, Tesch H, Renz D, Doerfler W.; 1991 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51957
·
Domains with Transcriptional Regulatory Activity within the ALL1 and AF4 Proteins Involved in Acute Leukemia. by Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, Leshrkowitz D, Croce CM, Canaani E.; 1995 Dec 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40316
·
Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. by Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230467
74 Leukemia
·
Dual Transforming Activities of the FUS (TLS)-ERG Leukemia Fusion Protein Conferred by Two N-Terminal Domains of FUS (TLS). by Ichikawa H, Shimizu K, Katsu R, Ohki M.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84797
·
EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. by So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, Sham MH, Wiedemann LM, Chan LC.; 1997 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20128
·
Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity. by Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS, Newmark HL, Conney AH, Chang RL.; 1998 Apr 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20265
·
Efficient Transplantation of BCR-ABL-Induced Chronic Myelogenous LeukemiaLike Syndrome in Mice. by Gishizky ML, Johnson-White J, Witte ON.; 1993 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46380
·
ELL and EAF1 are Cajal Body Components That Are Disrupted in MLL-ELL Leukemia. by Polak PE, Simone F, Kaberlein JJ, Luo RT, Thirman MJ.; 2003 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153119
·
Endocarditis and Aortal Embolization Caused by Aspergillus terreus in a Patient with Acute Lymphoblastic Leukemia in Remission: Diagnosis by Peripheral-Blood Culture. by Schett G, Casati B, Willinger B, Weinlander G, Binder T, Grabenwoger F, Sperr W, Geissler K, Jager U.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105327
·
Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of TCell Leukemia by Notch1. by Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS.; 2000 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86303
·
ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors. by Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=109299
·
ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain. by Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW.; 2001 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=99794
Studies
75
·
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. by Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM.; 1998 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27986
·
Expression of a gene encoding a tRNA synthetase-like protein is enhanced in tumorigenic human myeloid leukemia cells and is cell cycle stage- and differentiation-dependent. by Sen S, Zhou H, Ripmaster T, Hittelman WN, Schimmel P, White RA.; 1997 Jun 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21020
·
Expression of Alternatively Spliced Human T-Lymphotropic Virus Type I pX mRNA in Infected Cell Lines and in Primary Uncultured Cells from Patients with Adult TCell Leukemia/Lymphoma and Healthy Carriers. by Berneman ZN, Gartenhaus RB, Reitz MS Jr, Blattner WA, Manns A, Hanchard B, Ikehara O, Gallo RC, Klotman ME.; 1992 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48792
·
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. by Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A, Sensel M, Reaman GH, Uckun FM.; 1999 Jan 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15196
·
Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder. by Hao SX, Ren R.; 2000 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85233
·
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. by Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de la Chapelle A, Krahe R.; 2001 Jan 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=14719
·
Fatal Penicillium citrinum pneumonia with pericarditis in a patient with acute leukemia. by Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickham NW.; 1997 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230029
·
Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. by Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M.; 1998 Apr 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22533
·
Friend Leukemia Virus Infection Enhances DNA Damage-Induced Apoptosis of Hematopoietic Cells, Causing Lethal Anemia in C3H Hosts. by Kitagawa M, Yamaguchi S, Hasegawa M, Tanaka K, Sado T, Hirokawa K, Aizawa S.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=136359
76 Leukemia
·
Functional Analysis of the Leukemia Protein ELL: Evidence for a Role in the Regulation of Cell Growth and Survival. by Johnstone RW, Gerber M, Landewe T, Tollefson A, Wold WS, Shilatifard A.; 2001 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86713
·
Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias. by Mao S, Frank RC, Zhang J, Miyazaki Y, Nimer SD.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84165
·
Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukemia translocation. by Hussey DJ, Moore S, Nicola M, Dobrovic A.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=60524
·
Fusion of the TEL Gene on 12p13 to the AML1 Gene on 21q22 in Acute Lymphoblastic Leukemia. by Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG.; 1995 May 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41818
·
Gene Targeting of X Chromosome-Linked Chronic Granulomatous Disease Locus in a Human Myeloid Leukemia Cell Line and Rescue by Expression of Recombinant gp91phox. by Zhen L, King AA, Xiao Y, Chanock SJ, Orkin SH, Dinauer MC.; 1993 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47666
·
Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. by Melet F, Motro B, Rossi DJ, Zhang L, Bernstein A.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231261
·
Generation of Novel Syncytium-Inducing and Host Range Variants of Ecotropic Moloney Murine Leukemia Virus in Mus spicilegus. by Jung YT, Kozak CA.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153962
·
Genes on Chromosomes 4, 9, and 19 Involved in 11q23 Abnormalities in Acute Leukemia Share Sequence Homology and/or Common Motifs. by Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM, Canaani E.; 1993 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46566
·
Genetic Control of a Mouse Serum Lipoprotein Factor That Inactivates Murine Leukemia Viruses: Evaluation of Apolipoprotein F as a Candidate. by Wu T, Lee CG, Buckler-White A, Kozak CA.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153798
Studies
77
·
Genetic Regulation of Long-Term Nonprogression in E-55 + Murine Leukemia Virus Infection in Mice. by Panoutsakopoulou V, Hunter K, Sieck TG, Blankenhorn EP, Blank KJ.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112957
·
Genomic DNA breakpoints in AML1 /RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. by Zhang Y, Strissel P, Strick R, Chen J, Nucifora G, Le Beau MM, Larson RA, Rowley JD.; 2002 Mar 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122474
·
Gris1, a New Common Integration Site in Graffi Murine Leukemia Virus-Induced Leukemias: Overexpression of a Truncated Cyclin D2 due to Alternative Splicing. by Denicourt C, Kozak CA, Rassart E.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=140601
·
Growth Inhibition and Induction of Differentiation of t(8;21) Acute Myeloid Leukemia Cells by the DNA-Binding Domain of PEBP2 and the AML1/MTG8(ETO) Specific Antisense Oligonucleotide. by Sakakura C, Yamaguchi-Iwai Y, Satake M, Bae S, Takahashi A, Ogawa E, Hagiwara A, Takahashi T, Murakami A, Makino K, Nakagawa T, Kamada N, Ito Y.; 1994 Nov 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45304
·
Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling. by Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, Aster JC.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=151540
·
Homeobox Gene Expression Plus Autocrine Growth Factor Production Elicits Myeloid Leukemia. by Perkins A, Kongsuwan K, Visvader J, Adams JM, Cory S.; 1990 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54963
·
Host Sequences Flanking the Human T-Cell Leukemia Virus Type 1 Provirus In Vivo. by Leclercq I, Mortreux F, Cavrois M, Leroy A, Gessain A, Wain-Hobson S, Wattel E.; 2000 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=111712
·
Human AML1 /MDS1 /EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. by Cuenco GM, Nucifora G, Ren R.; 2000 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26509
·
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. by Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM.; 2002 May 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124510
·
Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling. by Doucas V, Evans RM.; 1999 Mar 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15820
78 Leukemia
·
Human T-Cell Leukemia Virus Type 1 Tax and Cell Cycle Progression: Role of Cyclin D-cdk and p110Rb. by Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT.; 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108944
·
Human T-Cell Leukemia Virus Type 1 Tax Induction of NF-[kappa]B Involves Activation of the I[kappa]B Kinase [alpha] (IKK[alpha]) and IKK[beta] Cellular Kinases. by Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET Jr, Grant M, Connelly MA, Hambor JE, Marcu KB, Greene WC.; 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=109101
·
Hypermutability of Mouse Chromosome 2 During the Development of X-RayInduced Murine Myeloid Leukemia. by Rithidech K, Bond VP, Cronkite EP, Thompson MH, Bullis JE.; 1995 Feb 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42656
·
Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia. by Reuther GW, Lambert QT, Caligiuri MA, Der CJ.; 2000 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86471
·
Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene. by Arakawa H, Nakamura T, Zhadanov AB, Fidanza V, Yano T, Bullrich F, Shimizu M, Blechman J, Mazo A, Canaani E, Croce CM.; 1998 Apr 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22531
·
Identification and Mapping of a Common Proviral Integration Site Fli-1 in Erythroleukemia Cells Induced by Friend Murine Leukemia Virus. by Ben-David Y, Giddens EB, Bernstein A.; 1990 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53469
·
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. by Chen W, Qin H, Chesebro B, Cheever MA.; 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190847
·
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: Evidence for its fusion with MLL in acute myeloid leukemia. by Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA.; 2000 Feb 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15768
·
Identification of Directly Infected Cells in the Bone Marrow of Neonatal Moloney Murine Leukemia Virus-Infected Mice by Use of a Moloney Murine Leukemia VirusBased Vector. by Okimoto MA, Fan H.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=103987
·
Identification of Genetic Determinants Responsible for the Rapid Immunosuppressive Activity and the Low Leukemogenic Potential of a Variant of